

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 March 2005 (17.03.2005)

PCT

(10) International Publication Number
WO 2005/024002 A1

(51) International Patent Classification⁷: **C12N 5/10**,
A23K 1/17, C07K 14/47, C12N 15/62, 9/90, A23K 1/00,
C12N 15/82, A01K 67/027, C07K 1/107

Per, Hølse [DK/DK]; Søborg Park Allé 60, DK-2860
Søborg (DK).

(21) International Application Number:
PCT/DK2004/000605

(74) Common Representative: **NOVOZYMES A/S**;
Krogshøjvej 36, DK-2880 Bagsvaerd (DK).

(22) International Filing Date:
13 September 2004 (13.09.2004)

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2003 01310 11 September 2003 (11.09.2003) DK

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US):
NOVOZYMES A/S [DK/DK]; Krogshøjvej 36, DK-2880
Bagsvaerd (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **JENSEN, Ejner,
Bech** [DK/DK]; Bernhard Olsensvej 16, DK-2830 Virum
(DK). **HØGENHAUG, Hans-Henrik, Kristensen**
[DK/DK]; Kong Valdemarsvej 16, DK-2840 Holte (DK).
HANSEN, Peter, Kamp [DK/DK]; Store Stensager 22,
DK-4320 Lejre (DK). **PEDERSEN, Poul, Erik** [DK/DK];
Marieborg Allé 33, DK-2860 Søborg (DK). **MYGIND,**

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: RECOMBINANT PRODUCTION OF ANTIMICROBIAL AGENTS

(57) Abstract: The invention relates to the use of co-expression of an antimicrobial agent and an enzyme, with a view to improving yield and/or overall production economy. Examples of antimicrobial agents are antimicrobial peptides such as lactoferricins and antimicrobial enzymes such as lysozyme and glucose oxidase, and examples of enzymes are endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, alpha-galactosidase, pectate lyase, alpha-amylase and glucoamylase. A fusion product comprising the antimicrobial agent and the enzyme and a cleavable linker is novel, and can be used in animal feed and animal feed additives. The invention also describes the use of a protection domain wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D (Asp) and/or E (Glu). The protection or quenching domain serves to temporarily and reversibly inactivate the antimicrobial peptide during the expression.



WO 2005/024002 A1

RECOMBINANT PRODUCTION OF ANTIMICROBIAL AGENTS**Field of the Invention**

The present invention relates to the field of recombinant production of antimicrobial agents, in particular to co-expression of antimicrobial agents and enzymes, as well as to the use of a protection domain wherein at least 50% of the amino acid residues comprised in the domain are D (asparagin, Asp) and/or E (glutamine, Glu).

Background of the Invention10 Background Art

WO 96/14413 discloses various expression vectors used to express recombinant human lactoferrin in various strains of *Aspergillus*. One expression plasmid, for expression in *Aspergillus awamori*, contains the glucoamylase promoter, signal sequence, and sequence encoding 498 amino acids of the endogenous pro-glucoamylase of *Aspergillus awamori*, fused to human lactoferrin. For expression of human lactoferrin in *Aspergillus oryzae*, the expression plasmid incorporates the *Aspergillus oryzae* AMY II gene that encodes the alpha-amylase promoter, secretory signal sequence and first codon of mature alpha-amylase. For expression of human lactoferrin in *Aspergillus nidulans*, the expression plasmid incorporates 300 bp of the 5'-flanking sequence of the *A. nidulans* *alcA* gene containing all the regulatory elements necessary for controlled gene expression, including the alcohol dehydrogenase promoter from *A. nidulans*.

WO 96/28559 discloses the expression of certain cationic antimicrobial proteins as fusion proteins with an anionic portion for suppressing the anti-microbial activity of the cationic protein. Examples of anionic carrier peptides are glutathione-S-transferase, protein A from *Staphylococcus aureus*, two synthetic IgG-binding domains (ZZ) of protein A, and outer membrane protein F from *Pseudomonas aeruginosa*.

WO 98/54336 discloses the expression of certain antimicrobial proteins as fusion proteins with a negatively charged acidic peptide having at least two cysteine residues.

WO 00/75344 discloses the expression of an exogenous polypeptide as fusions with pectate lyase using various linkers, for example (repeats of) PEPT (SEQ ID NO: 79), EPTP (SEQ ID NO: 80), PTEP (SEQ ID NO: 81), TPEP (SEQ ID NO: 82) or IEGR (SEQ ID NO: 83). Examples of exogenous polypeptides are single chain human insulin, human GLP1, and various alpha-amylases.

Okamoto et al in *Plant Cell Physiol.* 39(1):57-63 (1998) discloses the expression of the antimicrobial peptide Sarcotoxin IA by GUS fusion in transgenic tobacco plants. GUS designates the protein coding sequence of beta-glucuronidase.

It is an object of the present invention to provide improved methods for production of antimicrobial agents.

Summary of the Invention

5 In a first aspect, the invention relates to a recombinant microbial host cell comprising a first nucleic acid sequence encoding an antimicrobial agent, and a second heterologous nucleic acid sequence encoding an enzyme. Either of the nucleic acid sequences, preferably both, may be integrated into the chromosome of the host cell, or they may be present in one or more extrachromosomal entities.

10 In a second aspect, the invention relates to a nucleic acid construct comprising a first nucleic acid sequence encoding an antimicrobial agent, and a second nucleic acid sequence encoding an enzyme, operably linked to one or more control sequences that direct the expression of the enzyme and the antimicrobial agent in a suitable expression host, wherein the second nucleic acid sequence is heterologous to the expression host.

15 In a third aspect, the invention relates to a method of producing the enzyme and/or the antimicrobial agent by use of the recombinant host cell of the invention.

In a fourth aspect, the invention relates to fusion products comprising an enzyme, an antimicrobial agent, and a cleavable linker, as well as the use thereof in animal feed and animal feed additives.

20 In a fifth aspect, the invention relates to the use of co-expression of an antimicrobial peptide and an enzyme as a tool to improve the yield of the peptide and/or to improve overall production economy.

In a sixth aspect, the invention relates to the use, in the recombinant production of an antimicrobial peptide, of a quenching domain serving to temporarily and reversibly inactivate
25 the peptide during its expression, wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D and/or E. The invention also relates to a method of identifying such quenching domains, the quenching domains as identified by the method, and their use in the recombinant production of antimicrobial peptides.

30 Detailed Description of the Invention

Generally, whenever "a" is mentioned herein it means "at least one," for example in the context of the first and second nucleic acid sequences, the antimicrobial agent, the enzyme, and the various DNA constructs.

The present invention relates to the co-expression of at least one enzyme with at least
35 one antimicrobial agent. The enzyme and the antimicrobial agent may be co-expressed from the chromosome of the host cells, from different DNA constructs, from one DNA construct, or using a mixture of these techniques. When using different constructs, different selectable

markers, and different origins of replication may be used. When using only one construct, the genes can be expressed from one or more promoters. If cloned under the regulation of one promoter (di- or multi-cistronic), the order in which the genes are cloned may affect the expression levels of the proteins. The enzyme and the antimicrobial agent may also be expressed as a fusion protein, i.e. that the gene encoding the enzyme has been fused in frame to the gene encoding the antimicrobial agent. If the antimicrobial agent would negatively influence the growth of the host cell chosen, the antimicrobial activity can be quenched by expressing the peptide as a fusion with a protection peptide (a quenching domain) wherein at least 50% of the amino acid residues are D and/or E (Asp and/or Glu).

10

Antimicrobial Agent

In the present context, the term an antimicrobial agent designates a compound with antimicrobial activity (see below). Examples of antimicrobial agents are antimicrobial peptides and antimicrobial enzymes.

15

Examples of antimicrobial enzymes are enzymes which disrupt the cell wall, generate toxic compounds, remove essential nutrients, or inactivate compounds essential for growth of undesired microorganisms. Lysozyme (an enzyme having 1,4-beta-acetylmuramidase activity) is an example of an antimicrobial enzyme which disrupts the cell wall of grampositive bacteria. Oxidases, such as glucose oxidase (EC 1.1.3.4), generate hydrogen peroxide which is toxic to many undesired microorganisms. Other examples of antimicrobial enzymes which generate toxic compounds are xanthine oxidase, lactoperoxidase, lipase, myeloperoxidase, and phospholipase. Glucose oxidase is also an example of an enzyme which removes essential nutrients, namely oxygen, thereby preventing growth of aerobic undesired microorganisms. Finally, sulfhydryloxidase is an example of an antimicrobial enzyme which is capable of inactivating essential compounds, viz. those essential enzymes of the undesired microorganism, the activity of which depend on intact sulfhydryl groups. These enzymes are well-known and have been recombinantly produced, see for example for lysozyme and glucose oxidase Bio/Technology 8, 1990, 741-745, and WO 89/12675, respectively.

20

25

In a particular embodiment, the antimicrobial enzyme is selected from amongst lysozymes, glucose oxidases, sulphhydryl oxidases, peroxidases, and xanthine oxidases, preferably the antimicrobial enzyme is a lysozyme and/or a glucose oxidase.

30

Turning now to the antimicrobial peptides, in a particular embodiment, the antimicrobial peptides for use according to the invention encompass no more than 100 amino acids.

35

The expression "encompasses no more than" a certain number of amino acids (e.g. 100) means that the number of amino acids in the peptide sequence is less than or equal to 100.

In particular embodiments, the peptide comprises, or has, or consists of no more than 100 amino acids (and vice-versa for the additional upper limit figures mentioned below).

In further particular embodiments, the peptide encompasses no more than 90, 80, 70, 60, 50, or no more than 40 amino acids.

5 The peptide may also be designated an oligopeptide.

In another particular embodiment, the peptide encompasses at least 3 amino acids.

The expression "encompasses at least" a certain number of amino acids (e.g. 3) means that the number of amino acids in the peptide sequence is higher than or equal to 3.

10 In additional particular embodiments, the peptide encompasses at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or at least 20 amino acids.

In still further particular embodiments, the peptide comprises, or has, or consists of at least 3 amino acids (and vice-versa for the additional lower limit figures mentioned above).

Examples of antimicrobial peptides for use according to the invention are listed below.

15 **Antimicrobial Activity**

The term "antimicrobial activity" is defined herein as an activity which is capable of killing or inhibiting growth of microbial cells. In the context of the present invention the term "antimicrobial" is intended to mean that there is a bactericidal and/or a bacteriostatic and/or fungicidal and/or fungistatic effect and/or a virucidal effect.

20 The term "bactericidal" is to be understood as capable of killing bacterial cells. The term "bacteriostatic" is to be understood as capable of inhibiting bacterial growth, i.e. inhibiting growing bacterial cells. The term "fungicidal" is to be understood as capable of killing fungal cells. The term "fungistatic" is to be understood as capable of inhibiting fungal growth, i.e. inhibiting growing fungal cells. The term "virucidal" is to be understood as capable of
25 inactivating virus. The term "microbial cells" denotes bacterial or fungal cells (including yeasts).

In the context of the present invention the term "inhibiting growth of microbial cells" is intended to mean that the cells are in the non-growing state, i.e., that they are not able to propagate.

30 For purposes of the present invention, antimicrobial activity may be determined according to the procedure described by Lehrer et al., Journal of Immunological Methods, Vol. 137 (2) pp. 167-174 (1991).

Peptides, and/or enzymes, having antimicrobial activity may be capable of reducing the number of living cells of *Escherichia coli* (DSM 1576) to 1/100 after 8 hours (preferably after 4
35 hours, more preferably after 2 hours, most preferably after 1 hour, and in particular after 30 minutes incubation at 20°C in an aqueous solution of 25%(w/w); preferably in an aqueous solution of 10%(w/w); more preferably in an aqueous solution of 5%(w/w); even more

preferably in an aqueous solution of 1%(w/w); most preferably in an aqueous solution of 0.5%(w/w); and in particular in an aqueous solution of 0.1%(w/w) of the peptides having antimicrobial activity.

5 Peptides, and/or enzymes, having antimicrobial activity may also be capable of inhibiting the outgrowth of *Escherichia coli* (DSM 1576) for 24 hours at 25°C in a microbial growth substrate, when added in a concentration of 1000 ppm; preferably when added in a concentration of 500 ppm; more preferably when added in a concentration of 250 ppm; even more preferably when added in a concentration of 100 ppm; most preferably when added in a concentration of 50 ppm; and in particular when added in a concentration of 25 ppm.

10 Peptides, and/or enzymes, having antimicrobial activity may be capable of reducing the number of living cells of *Bacillus subtilis* (ATCC 6633) to 1/100 after 30 min. incubation at 20°C in an aqueous solution of 25%(w/w); preferably in an aqueous solution of 10%(w/w); more preferably in an aqueous solution of 5%(w/w); even more preferably in an aqueous solution of 1%(w/w); most preferably in an aqueous solution of 0.5%(w/w); and in particular in
15 an aqueous solution of 0.1%(w/w) of the peptides having antimicrobial activity.

Peptides, and/or enzymes, having antimicrobial activity may also be capable of inhibiting the outgrowth of *Bacillus subtilis* (ATCC 6633) for 24 hours at 25°C in a microbial growth substrate, when added in a concentration of 1000 ppm; preferably when added in a concentration of 500 ppm; more preferably when added in a concentration of 250 ppm; even
20 more preferably when added in a concentration of 100 ppm; most preferably when added in a concentration of 50 ppm; and in particular when added in a concentration of 25 ppm.

A detailed assay for antimicrobial activity is described in Example 1.

In a particular embodiment, as an alternative to the antimicrobial activity, or in addition to the antimicrobial activity, the peptide, and/or the enzyme, has an immunostimulatory effect.
25 This immunostimulatory effect can be mediated through an increase in the oxidative burst in macrophages or alternatively through an increased proliferation of lymphocytes.

Examples of antimicrobial peptides (AMPs) are membrane-active antimicrobial peptides, or antimicrobial peptides affecting/interacting with intracellular targets, e.g. binding to cell DNA. They generally have low hemolytic activity and/or cytotoxicity against normal
30 mammalian cells. Haemolysis is performed on erythrocytes and measured through the release of hemoglobin. Cytotoxicity is performed on relevant cell lines, e.g. human ME180 cervical epithelial cells (ATCC HTB-33) or A549 human lung epithelial cells (ATCC CCL-185) using a tetrazolium reduction assay (Boeringer-Mannheim, Indianapolis, USA).

The antimicrobial peptide for use according to the invention is generally highly cationic
35 and hydrophobic. It typically contains several arginine and lysine residues, and it may not contain a single glutamate or aspartate. It usually contains a large proportion of hydrophobic

residues. The peptide generally has an amphiphilic structure, with one surface being highly positive and the other hydrophobic.

The peptide and the encoding nucleotide sequence may be derived from plants, invertebrates, insects, amphibians and mammals, or from microorganisms such as bacteria
5 and fungi.

The antimicrobial peptide may act on cell membranes of target microorganisms, e.g. through non-specific binding to the membrane, usually in a membrane-parallel orientation, interacting only with one face of the bi-layer.

The antimicrobial peptide typically has a structure belonging to one of five major
10 classes: Alpha-helical, cystine-rich (defensin-like), beta-sheet, peptides with an unusual composition of regular amino acids, and peptides containing uncommon and/or modified amino acids. Still further examples are the antifungal peptides (AFP) from *Aspergillus giganteus* and *Aspergillus niger*, for example those disclosed in WO 02/090384.

In particular embodiments, the antimicrobial peptide for use according to the invention
15 is (i) an alpha-helical peptide, (ii) cystine-rich peptide; (iii) a beta-sheet peptide; (iv) a peptide with an unusual composition of regular amino acids; (v) a peptide containing uncommon modified amino acids; and/or (vi) an antifungal peptide.

In another particular embodiment (vii), the alpha-helical peptide is selected from
20 amongst Novispirin, Magainin 1, Magainin 2, Cecropin A, Cecropin B, Cecropin P1, CAP18, Andropin, Clavanin A, Clavanin AK, Styelin D, Styelin C, Buforin II, and the antimicrobial peptides described in WO 02/000839, DK 2004 000800, PCT/DK2004/000399, and/or PCT/DK2004/000400; as well as any variant or fragment thereof which retains antimicrobial activity.

In a further particular embodiment (viii), the cystine-rich peptide is selected from
25 amongst Plectasin, alpha-Defensin, HNP-1 (human neutrophil peptide), HNP-2, HNP-3, beta-Defensin-12, Drosomycin, gamma1-purothionin, Insect defensin A, and/or the antimicrobial peptides described in WO 03/044049; as well as any variant or fragment thereof which retains antimicrobial activity.

In another particular embodiment (ix), the peptide with an unusual composition is
30 selected from amongst Indolicidin, the Pro-Arg-rich peptide PR39, Bactenecin Bac5, Bactericin Bac7, Histatin 5; poly-L-lysine, and/or the antimicrobial peptides described in DK 2003 001324; as well as any variant or fragment thereof which retains antimicrobial activity.

In a still further particular embodiment (x), the peptide with unusual amino acids is
35 selected from amongst Nisin, Gramicidin A, and/or Alamethicin; as well as any variant or fragment thereof which retains antimicrobial activity.

In an additional particular embodiment (xi), the peptide is an antifungal peptide.

In a still further particular embodiment (xii), the expressed peptide is free of any protecting scaffold proteins.

In a particular embodiment (xiii), the peptide has antimicrobial activity and/or an immunostimulatory effect.

5 In a still further particular embodiment (xiv), the beta-sheet peptide is selected from amongst lactoferrins, lactoferricins (such as Lactoferricin B), Tachyplesin I, and/or Protegrin PG1-5; as well as any variant or fragment thereof which retains antimicrobial activity.

Lactoferrin is a glycoprotein involved in iron binding and delivery in mammals, where it is found in milk and other body fluids. Examples of lactoferrins are human lactoferrin, bovine
10 lactoferrin, porcine lactoferrin, equine lactoferrin, murine lactoferrin, caprine lactoferrin etc. Lactoferrin was described as an antimicrobial agent more than 20 years ago.

The term lactoferricin as used herein designates fragments of lactoferrin having antimicrobial activity and/or an immunostimulatory effect. In a particular embodiment, the lactoferricin for use according to the invention is derived from Bovine lactoferrin (LFB), a
15 protein of 689 amino acids, which has been produced industrially from cheese whey and supplemented to infant formula for a number of years.

A number of examples of lactoferricins for use according to the invention are listed below (a non-exclusive list):

SEQ ID NOs: 1-4 disclosed in EP 474506 are antimicrobial peptides produced by
20 hydrolysis of lactoferrin;

SEQ ID NOs: 5-19, as well as their derivatives having an amide at the carboxy end, disclosed in EP 503939, are antimicrobial peptides based on amino acids 18-28 of Bovine lactoferrin (LFB(18-28));

SEQ ID NOs: 20-31, as well as their derivatives having an amide at the carboxy end,
25 disclosed in EP 510912, are antimicrobial peptides obtainable by hydrolysis from bovine lactoferrin;

SEQ ID NO: 32 disclosed in EP 629213 is another lactoferrin derivative for the manufacture of a medicament for promoting release of leukotriene B4 from polymorphonuclear neutrophils or histamine from mast cells;

30 SEQ ID NOs: 1-4, SEQ ID NO: 15, SEQ ID NOs: 20-32, and SEQ ID NOs: 33-46 disclosed in US patent no. 5,656,591 are additional examples of antimicrobial peptides based on lactoferrin.

SEQ ID NO: 47 is amino acids 1-50 of bovine lactoferrin (LFB(1-50)), and lactoferricin B (abbreviated LFcinB, or LFB(17-41)) designates amino acids 17-41 of SEQ ID NO: 47.

35 SEQ ID NOs: 48-52, viz. LFB(14-31), LFB(17-31), LFB(18-31), LFB(19-31), and LFB(20-31), respectively, are additional lactoferrin fragments disclosed in J. Peptide Sci. 5:

32-45 (1999) by Rekdal et al, who also discloses SEQ ID NOs: 53-55, viz. variants LFB(17-31)17K, LFB(17-31)20F, and LFB(17-31)17K+20F, respectively.

Additional lactoferricins, e.g. SEQ ID NOs. 56-57, viz. LFB(17-30), and LFB(19-37), respectively, are disclosed by Groenink et al in FEMS Microbiology Letters 179 (1999) 217-222.

According to Vogel et al (Biochem. Cell. Biol. 80 (2002): 49-63), a fragment of LFB must contain the six amino acids 20-25 thereof (LFB(20-25), SEQ ID NO: 58) in order to retain any practical level of antimicrobial activity.

A number of variants of LFB(17-31) are disclosed by Stroem et al in J. Peptide Res. 2000, 56, 265-274, viz. 17A, 18A, 19A, 20A, 21A, 22A, 23A, 24A, 25A, 26A, 27A, 28A, 29A, 30A, and 31A.

Additional variants of LFB(17-31) are disclosed by Haug and Svendsen in J. Peptide Sci. 7: 190-196 (2001), viz. 22F, 24F, and 22F+24F.

In particular embodiments, the antimicrobial peptide for use according to the invention (a) comprises SEQ ID NO: 58; (b) comprises SEQ ID NO: 47, and/or a fragment or variant thereof; (c) comprises any one of SEQ ID NOs: 48-52, SEQ ID NOs: 56-57, and/or a fragment or variant thereof.

Enzymes

An enzyme is a polypeptide having enzyme activity. Other protein products of interest for the purposes of the present invention (co-expression with antimicrobial agents) are hormones, blood clotting factors, immunoglobulins, as well as fragments or variants thereof.

The following is a non-limiting list of examples of enzymes of particular interest: Endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, and alpha-galactosidase. Additional enzymes of particular relevance are pectate lyase, alpha-amylase and AMG. In a particular embodiment, the enzyme is a xylanase, a phytase, a galactanase, or a protease. In a still further particular embodiment, the enzyme is a phytase, or a protease. In a still further particular embodiment the enzyme is not glutathione-S-transferase. In another particular embodiment the enzyme is not beta-glucuronidase.

There are no limitations on the origin of the enzyme. Thus, the term includes not only natural or wild-type enzymes obtained from microorganisms of any genus, but also any analogues, mutants, variants, fragments etc. thereof, as well as synthetic enzymes, such as shuffled enzymes, and consensus enzymes, as long as they exhibit the relevant enzyme activity. Such genetically engineered enzymes can be prepared as is generally known in the art, eg by Site-directed Mutagenesis, by PCR, or by Random Mutagenesis.

In a particular embodiment, the enzyme, and/or the nucleotide sequence encoding it, is a heterologous, or exogenous, enzyme and/or nucleotide sequence, respectively. This means

that it is foreign to the selected or intended expression host cell. The term heterologous excludes natural or wild-type nucleic acid sequences endogenous to the host cell in question.

In a specific embodiment, the enzyme is a low-allergenic variant, designed to invoke a reduced immunological response when exposed to animals, including man. Low-allergenic variants may be prepared using techniques known in the art.

Enzymes can be classified on the basis of the handbook Enzyme Nomenclature from NC-IUBMB, 1992), see also the ENZYME site at the internet: <http://www.expasy.ch/enzyme/>. ENZYME is a repository of information relative to the nomenclature of enzymes. It is primarily based on the recommendations of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (IUB-MB) and it describes each type of characterized enzyme for which an EC (Enzyme Commission) number has been provided (Bairoch A. The ENZYME database, 2000, Nucleic Acids Res 28:304-305). This IUB-MB Enzyme nomenclature is based on their substrate specificity and occasionally on their molecular mechanism; such a classification does not reflect the structural features of these enzymes.

For the present purposes a xylanase is an enzyme classified as EC 3.2.1.8. The xylanase may be derived from a bacterial xylanase, e.g. from a strain of Bacillus, or it may be a fungal xylanases including yeast and filamentous fungal xylanases. Fungal xylanases can, e.g., be derived from a strain of Aspergillus, Humicola, Thermomyces, or Trichoderma.

For the present purposes, the term endoglucanase designates any enzyme which is classified or can be classified as EC 3.2.1.4, EC 3.2.1.6, EC 3.2.1.73, or EC 3.2.1.39. In particular embodiments, the endoglucanase is an enzyme classified as EC 3.2.1.4 or EC 3.2.1.6. Endoglucanases may be derived from various fungal and bacterial strains, e.g. from strains of Thermoascus.

The term protease as used herein is an enzyme that can be classified in the EC 3.4 enzyme group. Examples of proteases are Aspergillus aculeatus protease I or protease II; Aspergillus niger acid proteinase (protease A)); Aspergillus oryzae aspergillopepsin O; the acid-stable subtilisin proteases disclosed at p. 5, lines 19-23 of WO 01/58275 derived from Bacillus sp., Bacillus alcalophilus; Fusarium oxysporum; Paecilomyces lilacinus, Aspergillus sp., Acremonium chrysogenum, and Acremonium kiliense; and the acid-stable proteases disclosed in WO 01/58276 at p. 4, line 27-28 derived from Nocardiosis sp. and Nocardiosis alba.

The Nocardiosis sp. protease comprises the amino acid sequence of the mature part (amino acids 1-188) of SEQ ID NO: 59. A preferred protease is A87T of SEQ ID NO: 59, viz. a variant of the protease having amino acids 1-188 of SEQ ID NO: 59 in which Ala in position 87 is substituted with Thr.

Other preferred proteases are the following:

The protease derived from *Nocardiosis dassonvillei* subsp. *dassonvillei* and comprising the amino acid sequence of the mature part (amino acids 1-188) of SEQ ID NO: 60.

5 The protease derived from *Nocardiosis alba* and comprising the amino acid sequence of the mature part (amino acids 1-188) of SEQ ID NO: 61.

The protease derived from *Nocardiosis prasina* and comprising the amino acid sequence of the mature part (amino acids 1-188) of SEQ ID NO: 62.

A protease derived from *Nocardiosis prasina* and comprising the amino acid sequence of the mature part (amino acids 1-188) of SEQ ID NO: 63.

10 In a particular embodiment, the proteases of SEQ ID NO: 59, 60, 61, 62 or 63 are variants comprising an extension, such as an N- or C-terminal extension, preferably a C-terminal extension. The extension may comprise at least three non-polar or uncharged polar amino acids within the last four amino acids of the C-terminus of the polypeptide, in particular these variants have an extension of one or more amino-acid(s) added to the C-terminus as
15 compared to the wildtypes. In further particular embodiments:

i) the one or more added amino acid(s) is (are) non-polar or uncharged;

ii) the one or more added amino acid(s) is one or more of Q, S, V, A, or P;

iii) the one or more added amino acids are selected from the group consisting of: QSHVQSAP (SEQ ID NO: 84), QSAP (SEQ ID NO: 85), QP, TL, TT, QL, TP, LP, TI, IQ, QP,
20 PI, LT, TQ, IT, QQ, and PQ.

In a still further embodiment, the protease has a degree of identity to amino acids 1-188 of SEQ ID NO: 59 of at least 70%, preferably at least 75%, 80%, 85%, 90%, or at least 95%.

For purposes of the present invention the degree of identity between two amino acid
25 sequences is determined by the program "align" which is a Needleman-Wunsch alignment (i.e. a global alignment). The default scoring matrix BLOSUM50 is used for polypeptide alignments. The penalty for the first residue of a gap is -12 for polypeptides, and the penalty for further residues of a gap is -2 for polypeptides.

"Align" is part of the FASTA package version v20u6 (see W. R. Pearson and D. J. Lipman (1988), "Improved Tools for Biological Sequence Analysis", PNAS 85:2444-2448, and W. R. Pearson (1990) "Rapid and Sensitive Sequence Comparison with FASTP and FASTA," Methods in Enzymology 183:63- 98). FASTA protein alignments use the Smith-Waterman algorithm with no limitation on gap size (see "Smith-Waterman algorithm", T. F. Smith and M. S. Waterman (1981) J. Mol. Biol. 147:195-197).

35 In the present context a phytase is an enzyme which can be classified as EC 3.1.3.8, and/or EC 3.1.3.26. Phytases may be obtained from, e.g., various strains of *Aspergillus* and

Emericella, Thermomyces, Humicola, Peniophora, Penicillium, Bacillus, Escherichia coli; or Schwanniomyces.

A preferred phytase derives from Peniophora lycii and comprises amino acids 1-409 of SEQ ID NO: 64, or is a variant thereof. In a particular embodiment, the variant is selected from
5 the variants disclosed in Tables 1-5 of WO 03/066847.

In a still further particular embodiment, the phytase has a degree of identity to amino acids 31-439 of SEQ ID NO: 64 of at least 75%.

The term galactanase as used herein is an enzyme that can be classified as EC 3.2.1.89. Galactanases may be derived from, e.g., strains of Aspergillus, Bacillus,
10 Thermotoga, Meripilus, Myceliophthora, Humicola, Pseudomonas, Xanthomonas, or Yersinia.

The term mannanase as used herein means an enzyme which can be classified as EC 3.2.1.78. The mannanase may, e.g., be derived from strains of Aspergillus, Bacillus, or Trichoderma.

The term dextranase as used herein means an enzyme which can be classified as EC
15 3.2.1.11. The dextranase may, e.g., be derived from a strain of Paecilomyces.

The term alpha-galactosidase as used herein means an enzyme that can be classified as EC 3.2.1.22. The alpha-galactosidase may, e.g., be derived from a strain of Aspergillus.

The term alpha-amylase as used herein is an enzyme that can be classified as EC
20 3.2.1.1.

The term glucoamylase as used herein is an enzyme that can be classified as EC
3.2.1.3.

The term pectate lyase as used herein is an enzyme that can be classified as EC
4.2.2.2.

Strains of the species mentioned above and other strains mentioned herein are readily
25 accessible to the public in a number of culture collections, such as the American Type Culture Collection (ATCC), Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ), Centraalbureau Voor Schimmelcultures (CBS), and Agricultural Research Service Patent Culture Collection, Northern Regional Research Center (NRRL).

30 **Nucleic Acid Sequences**

The nucleic acid sequences for use in the present invention may be of genomic, cDNA, RNA, semisynthetic, synthetic origin, or any combinations thereof.

The techniques used to isolate or clone a nucleic acid sequence encoding an antimicrobial agent or an enzyme are known in the art and include isolation from genomic
35 DNA, preparation from cDNA, chemical synthesis, or a combination thereof. Most of the peptide genes are synthesized chemically. Peptide genes found by signal trapping (e.g. TAST, i.e. Transposon Assisted Signal Trapping) is of natural origin.

The cloning of the nucleic acid sequences from such genomic DNA can be effected, e.g., by using the well known polymerase chain reaction (PCR) or antibody screening of expression libraries to detect cloned DNA fragments with shared structural features. See, e.g., Innis et al., 1990, PCR: A Guide to Methods and Application, Academic Press, New York.

5 Other nucleic acid amplification procedures such as ligase chain reaction (LCR), ligated activated transcription (LAT) and nucleic acid sequence-based amplification (NASBA) may be used.

The nucleic acid sequence encoding the enzyme and/or the antimicrobial agent may, e.g., be cloned from a strain of the desired bacterium or fungus, or another or related
10 organism and thus, for example, may be an allelic or species variant.

The term "isolated nucleic acid sequence" as used herein refers to a nucleic acid sequence which is essentially free of other nucleic acid sequences, e.g., at least about 20% pure, preferably at least about 40% pure, more preferably at least about 60% pure, even more preferably at least about 80% pure, and most preferably at least about 90% pure as
15 determined by agarose electrophoresis. For example, an isolated nucleic acid sequence can be obtained by standard cloning procedures used in genetic engineering to relocate the nucleic acid sequence from its natural location to a different site where it will be reproduced. The cloning procedures may involve excision and isolation of a desired nucleic acid fragment comprising the nucleic acid sequence encoding the antimicrobial agent or the enzyme,
20 insertion of the fragment into a vector molecule, and incorporation of the recombinant vector into a host cell where multiple copies or clones of the nucleic acid sequence will be replicated.

Modification of a nucleic acid sequence encoding an antimicrobial agent or an enzyme as defined in claim 1 may be necessary for the synthesis of variant agents or variant enzymes. The terms "variant agent" and "variant enzyme" refer to non-naturally occurring forms of
25 thereof. These may differ in some engineered way from the antimicrobial agent or enzyme as isolated from its native source, e.g., agent or enzyme variants that differ in specific activity, thermostability, pH optimum, allergenicity, or agent variants that differ in antimicrobial activity or specificity profile, or the like. The variant sequence may be constructed on the basis of the nucleic acid sequences encoding the agent or the mature part of the enzyme, e.g., a
30 subsequence thereof, and/or by introduction of nucleotide substitutions which do not give rise to another amino acid sequence of the polypeptide encoded by the nucleic acid sequence, but which correspond to the codon usage of the host organism intended for production of the enzyme and agent, or by introduction of nucleotide substitutions which may give rise to a different amino acid sequence. For a general description of nucleotide substitution, see, e.g.,
35 Ford et al., 1991, Protein Expression and Purification 2: 95-107. Low-allergenic enzymes and antimicrobial agents can e.g. be prepared as described above.

It will be apparent to those skilled in the art that such substitutions can be made outside the regions critical to the function of the molecule and still result in an active agent or enzyme. Amino acid residues essential to the activity of the enzyme or antimicrobial agent encoded by the nucleic acid sequence, and therefore preferably not subject to substitution, may be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (see, e.g., Cunningham and Wells, 1989, *Science* 244: 1081-1085). In the latter technique, mutations are introduced at every positively charged residue in the molecule, and the resultant mutant molecules are tested for activity to identify amino acid residues that are critical to the activity of the molecule. Sites of substrate-enzyme interaction can also be determined by analysis of the three-dimensional structure as determined by such techniques as nuclear magnetic resonance analysis, crystallography or photoaffinity labelling (see, e.g., de Vos et al., 1992, *Science* 255: 306-312; Smith et al., 1992, *Journal of Molecular Biology* 224: 899-904; Wlodaver et al., 1992, *FEBS Letters* 309: 59-64).

15 **Nucleic Acid Constructs**

The present invention relates to nucleic acid constructs of a certain type, viz. constructs that comprise a first nucleic acid sequence encoding an antimicrobial agent, and a second nucleic acid sequence encoding an enzyme, operably linked to one or more control sequences that direct the expression of these coding sequences in a suitable host cell under conditions compatible with the control sequences. In a particular embodiment, the second nucleic acid sequence is heterologous to the expression host.

"Nucleic acid construct" is defined herein as a nucleic acid molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or which has been modified to contain segments of nucleic acid combined and juxtaposed in a manner that would not otherwise exist in nature. The term nucleic acid construct is synonymous with the term expression cassette when the nucleic acid construct contains all the control sequences required for expression.

The term "a nucleic acid sequence encoding" or "coding sequence" is defined herein as a nucleic acid sequence that directly specifies the amino acid sequence of its peptide or enzyme product. The boundaries of the coding sequence are generally determined by a ribosome binding site (prokaryotes) or by the ATG start codon (eukaryotes) located just upstream of the open reading frame at the 5' end of the mRNA and a transcription terminator sequence located just downstream of the open reading frame at the 3' end of the mRNA. A coding sequence can include, but is not limited to, DNA, cDNA, and recombinant nucleic acid sequences.

Expression will be understood to include any step involved in the production of the enzyme and the antimicrobial agent including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

The term "control sequences" is defined herein to include all components that are
5 necessary or advantageous for the expression of an enzyme, and an antimicrobial agent, respectively. Each control sequence may be native or foreign to the respective encoding nucleic acid sequence. Such control sequences include, but are not limited to, a leader, polyadenylation sequence, propeptide sequence, promoter, signal peptide sequence, and transcription terminator. At a minimum, the control sequences include a promoter, and
10 transcriptional and translational stop signals. The control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the nucleic acid sequence encoding a polypeptide. The term "operably linked" is defined herein as a configuration in which a control sequence is appropriately placed at a position relative to the coding sequence of the DNA sequence such
15 that the control sequence directs the expression of a polypeptide.

The control sequence may be an appropriate promoter sequence, a nucleic acid sequence that is recognized by a host cell for expression of the nucleic acid sequence. The promoter sequence contains transcriptional control sequences that mediate the expression of the polypeptide. The promoter may be any nucleic acid sequence which shows transcriptional
20 activity in the host cell of choice including mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.

Examples of suitable promoters for directing the transcription of the nucleic acid constructs of the present invention, especially in a bacterial host cell, are the promoters
25 obtained from the *E. coli* lac operon, *Streptomyces coelicolor* agarase gene (*dagA*), *Bacillus subtilis* levansucrase gene (*sacB*), *Bacillus licheniformis* alpha-amylase gene (*amyL*), *Bacillus stearothermophilus* maltogenic amylase gene (*amyM*), *Bacillus amyloliquefaciens* alpha-amylase gene (*amyQ*), *Bacillus licheniformis* penicillinase gene (*penP*), *Bacillus subtilis* *xylA* and *xylB* genes, and prokaryotic beta-lactamase gene (Villa-Kamaroff et al., 1978, Proceedings of the National Academy of Sciences USA 75: 3727-3731), as well as the *tac* promoter (DeBoer et al., 1983, Proceedings of the National Academy of Sciences USA 80: 21-25). Further promoters are described in "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242: 74-94; and in Sambrook et al., 1989, supra.
30

Examples of suitable promoters for directing the transcription of the nucleic acid
35 constructs of the present invention in a filamentous fungal host cell are promoters obtained from the genes for *Aspergillus oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *Aspergillus niger* neutral alpha-amylase, *Aspergillus niger* acid stable alpha-amylase,

Aspergillus niger or Aspergillus awamori glucoamylase (glaA), Rhizomucor miehei lipase, Aspergillus oryzae alkaline protease, Aspergillus oryzae triose phosphate isomerase, Aspergillus nidulans acetamidase, and Fusarium oxysporum trypsin-like protease (WO 96/00787), as well as the NA2-tpi promoter (a hybrid of the promoters from the genes for
5 Aspergillus niger neutral alpha-amylase and Aspergillus oryzae triose phosphate isomerase), and mutant, truncated, and hybrid promoters thereof.

In a yeast host, useful promoters are obtained from the genes for Saccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiae galactokinase (GAL1), Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydro-
10 genase (ADH2/GAP), and Saccharomyces cerevisiae 3-phosphoglycerate kinase. Other useful promoters for yeast host cells are described by Romanos et al., 1992, Yeast 8: 423-488.

The control sequence may also be a suitable transcription terminator sequence, a sequence recognized by a host cell to terminate transcription. The terminator sequence is operably linked to the 3' terminus of the nucleic acid sequence encoding the polypeptide. Any
15 terminator which is functional in the host cell of choice may be used in the present invention.

Preferred terminators for filamentous fungal host cells are obtained from the genes for Aspergillus oryzae TAKA amylase, Aspergillus niger glucoamylase, Aspergillus nidulans anthranilate synthase, Aspergillus niger alpha-glucosidase, and Fusarium oxysporum trypsin-like protease.

Preferred terminators for yeast host cells are obtained from the genes for Saccharomyces cerevisiae enolase, Saccharomyces cerevisiae cytochrome C (CYC1), and Saccharomyces cerevisiae glyceraldehyde-3-phosphate dehydrogenase. Other useful
20 terminators for yeast host cells are described by Romanos et al., 1992, supra.

Preferred terminators for bacterial host cells, such as a Bacillus host cell, are the terminators from Bacillus licheniformis alpha-amylase gene (amyL), the Bacillus stearothermo-
25 philus maltogenic amylase gene (amyM), or the Bacillus amyloliquefaciens alpha-amylase gene (amyQ).

The control sequence may also be a suitable leader sequence, a nontranslated region of an mRNA which is important for translation by the host cell. The leader sequence is
30 operably linked to the 5' terminus of the nucleic acid sequence encoding the polypeptide. Any leader sequence that is functional in the host cell of choice may be used in the present invention.

Preferred leaders for filamentous fungal host cells are obtained from the genes for Aspergillus oryzae TAKA amylase and Aspergillus nidulans triose phosphate isomerase.

Suitable leaders for yeast host cells are obtained from the genes for Saccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiae 3-phosphoglycerate kinase,
35

Saccharomyces cerevisiae alpha-factor, and Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP).

The control sequence may also be a polyadenylation sequence, a sequence operably linked to the 3' terminus of the nucleic acid sequence and which, when transcribed, is recognized by the host cell as a signal to add polyadenosine residues to transcribed mRNA. Any polyadenylation sequence which is functional in the host cell of choice may be used in the present invention.

Preferred polyadenylation sequences for filamentous fungal host cells are obtained from the genes for Aspergillus oryzae TAKA amylase, Aspergillus niger glucoamylase, Aspergillus nidulans anthranilate synthase, Fusarium oxysporum trypsin-like protease, and Aspergillus niger alpha-glucosidase.

Useful polyadenylation sequences for yeast host cells are described by Guo and Sherman, 1995, Molecular Cellular Biology 15: 5983-5990.

The control sequence may also be a signal peptide coding region that codes for an amino acid sequence linked to the amino terminus of an enzyme and directs the encoded enzyme into the cell's secretory pathway. The 5' end of the coding sequence of the nucleic acid sequence may inherently contain a signal peptide coding region naturally linked in translation reading frame with the segment of the coding region which encodes the secreted enzyme. Alternatively, the 5' end of the coding sequence may contain a signal peptide coding region which is foreign to the coding sequence. The foreign signal peptide coding region may be required where the coding sequence does not naturally contain a signal peptide coding region. Alternatively, the foreign signal peptide coding region may simply replace the natural signal peptide coding region in order to enhance secretion of the enzyme. However, any signal peptide coding region which directs the expressed enzyme into the secretory pathway of a host cell of choice may be used in the present invention.

Effective signal peptide coding regions for bacterial host cells are the signal peptide coding regions obtained from the genes for Bacillus NCIB 11837 maltogenic amylase, Bacillus stearothermophilus alpha-amylase, Bacillus licheniformis subtilisin, Bacillus licheniformis beta-lactamase, Bacillus stearothermophilus neutral proteases (nprT, nprS, nprM), and Bacillus subtilis prsA. Further signal peptides are described by Simonen and Palva, 1993, Microbiological Reviews 57: 109-137.

Effective signal peptide coding regions for filamentous fungal host cells are the signal peptide coding regions obtained from the genes for Aspergillus oryzae TAKA amylase, Aspergillus niger neutral amylase, Aspergillus niger glucoamylase, Rhizomucor miehei aspartic proteinase, Humicola insolens cellulase, and Humicola lanuginosa lipase.

Useful signal peptides for yeast host cells are obtained from the genes for *Saccharomyces cerevisiae* alpha-factor and *Saccharomyces cerevisiae* invertase. Other useful signal peptide coding regions are described by Romanos et al., 1992, supra.

The control sequence may also be a propeptide coding region that codes for an amino acid sequence positioned at the amino terminus of an enzyme. The resultant enzyme is known as a proenzyme or propolypeptide (or a zymogen in some cases). A proenzyme is generally inactive and can be converted to a mature active enzyme by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide coding region may be obtained from the genes for *Bacillus subtilis* alkaline protease (aprE), *Bacillus subtilis* neutral protease (nprT), *Saccharomyces cerevisiae* alpha-factor, *Rhizomucor miehei* aspartic proteinase, and *Myceliophthora thermophila* laccase (WO 95/33836).

Where both signal peptide and propeptide regions are present at the amino terminus of an enzyme, the propeptide region is positioned next to the amino terminus of an enzyme and the signal peptide region is positioned next to the amino terminus of the propeptide region.

It may also be desirable to add regulatory sequences which allow the regulation of the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory systems are those which cause the expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Regulatory systems in prokaryotic systems include the lac, tac, and trp operator systems. In yeast, the ADH2 system or GAL1 system may be used. In filamentous fungi, the TAKA alpha-amylase promoter, *Aspergillus niger* glucoamylase promoter, and *Aspergillus oryzae* glucoamylase promoter may be used as regulatory sequences. Other examples of regulatory sequences are those which allow for gene amplification. In eukaryotic systems, these include the dihydrofolate reductase gene which is amplified in the presence of methotrexate, and the metallothionein genes which are amplified with heavy metals. In these cases, the nucleic acid sequence encoding the enzyme would be operably linked with the regulatory sequence.

The nucleic acid construct of the invention may comprise more than one nucleic acid sequence encoding more than one enzyme, e.g. one, two, three, four, five, six, seven, eight, nine or ten nucleic acid sequences encoding one, two, three, four, five, six, seven, eight, nine or ten enzymes. The enzymes may be the same or different. The nucleic acid sequences encoding the enzyme(s) may be the same or different.

The nucleic acid construct of the invention may also comprise more than one nucleic acid sequence encoding more than one antimicrobial agent, e.g. one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty nucleic acid sequences encoding one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty antimicrobial agents. The nucleic acid construct of the invention may also

comprise more than twenty nucleic acid sequences encoding more than twenty antimicrobial agents, e.g. up to twenty-five, thirty, thirty-five, forty, forty-five, or even up to fifty nucleic acid sequences encoding up to twenty-five, thirty, thirty-five, forty, forty-five, or even up to fifty antimicrobial agents. The antimicrobial agents may be the same or different. The nucleic acid sequences encoding the antimicrobial agent(s) may be the same or different. The numbers of nucleic acid sequences may in particular be in the higher range when expression takes place in inclusion bodies.

In the nucleic acid construct of the invention, the nucleic acid sequence(s) encoding the enzyme(s) may be upstream of the nucleic acid sequence(s) encoding the antimicrobial agent(s), or vice versa. Still further, some of the enzyme encoding sequences may be upstream, some downstream, of the antimicrobial agent encoding sequences, and vice versa.

Of course, as is common general knowledge, in all nucleic acid constructs described herein the individual component sequences, such as the nucleic acid sequences encoding the enzyme(s), the antimicrobial agent(s), the control sequences, and also the linkers and domains described further below, should be properly spaced and juxtaposed so as to enable the desired, correct, expression to occur.

Three examples a)-c) of relatively simple nucleic acid constructs of the invention are listed below. The constructs are listed in the usual direction of 5' to 3', and the following abbreviations are used: AMP: Anti Microbial Peptide; ENZ: Enzyme; RBS: Ribosome Binding Site, PROM: Promoter; TERM: Terminator):

- a) PROM-RBS1-Gene(AMP)-Linker-Gene(ENZ)-TERM
- b) PROM-RBS1-Gene(AMP)-RBS2-Gene(ENZ)-TERM
- c) PROM1-RBS1-Gene(AMP)-TERM1-PROM2-RBS2-Gene(Enzyme)-TERM2

Ad a): This construct results in one transcriptional product, and one translational product, viz. a fusion protein (fusion product). In the above constructs, "Linker" designates a cleavable linker, which is described in more detail below, and which provides for subsequent cleavage of the fusion protein, AMP-Linker-ENZ, into distinct products, AMP, and ENZ, respectively.

Ad b): This construct results in one transcriptional product, but two translational products, as the translation will stop because of the translational stop codon inherent in Gene(AMP). Accordingly, two distinct products, AMP and ENZ, will be produced.

Ad c): In this construct, transcription will stop after Gene(AMP), but the transcription continues at PROM2. Accordingly, two transcription products, as well as two translational products, AMP and ENZ, result from this construct. By applying PROM1 and PROM2 promoters of varying strength, or by using one or more inducible promoters, the expression of AMP can be regulated as compared to ENZ, or vice versa, e.g. with a view to obtain desired molar ratios of expressed AMP versus ENZ.

The below constructs d)-f) are non-limiting examples of nucleic acid constructs of the invention incorporating more than one nucleic acid sequence encoding the enzyme and/or the peptide. The same notation as above applies, the control sequences, linkers etc. are however excluded for the sake of simplicity:

- 5 d) Gene(ENZ)-Gene(AMP)-Gene(AMP)
 e) Gene(ENZ)-Gene(AMP)-Gene(AMP)-Gene(AMP)
 f) Gene(ENZ)-Gene(AMP)-Gene(AMP)-Gene(AMP)-Gene(ENZ)

In the above constructs, AMP can designate the same or different AMP sequences, and the same holds true for ENZ.

10

Cleavable linkers

At the amino acid level, the term "cleavable linker" is defined herein as a sequence of amino acids, typically relatively short, e.g. consisting of 1-30 amino acids which comprises a cleavage site. The term "cleavage site" means a specific sequence of amino acids, typically
15 very short, e.g. consisting of 1-10 amino acids which can be cleaved specifically by a cleavage agent, viz. by physical or chemical, typically enzymatical, means. Non-limiting examples of cleavable linkers, recognition and cleavage sites, and cleavage agents are listed below.

For example, the cleavable linker can be a recognition site for a site-specific protease. An example of a site-specific protease (cleavage agent) is the Kex2 membrane bound
20 proteinase from alpha-cells of the yeast *Saccharomyces cerevisiae*. The Kex2 proteinase hydrolyzes peptides and proteins with basic amino acid pairs which are cleaved at the C-ends of their peptide bonds (Bessmertnaya et al. (1997) *Biochemistry*, Vol. 62 (8) pp. 850-857. Examples of Kex2 cleavage sites are Lys-Arg (K-/R) and Arg-Arg (R-/R), and also other combinations of basic amino acids could be inserted to optimize the cleavage by Kex2
25 (Ledgerwood. et al. (1995) *J.Biochem.*, Vol. 308 (1) pp. 321-325; or Ghosh, S. et al. (1996) *Gene (Amsterdam)*, Vol. 176 (1-2) pp. 249-255).

Other useful combinations of proteases (cleavage agents) and cleavage linkers are: Enterokinase (La Vallie et al. (1993) *J.Biol.Chem.*, Vol 268 pp.2311-2317) with a preference for cleaving the amino acid sequence X-D-D-D-K-/X (SEQ ID NO: 86), Trypsin (Jonasson et
30 al. (1996) *Eur.J.Biochem.*, Vol 236 (2) pp. 656-661) with a preference for cleaving the amino acid sequence X-K-R-/X (SEQ ID NO: 87), Factor Xa (Nagai et al. (1985) *PNAS*, Vol 82 pp. 7252-7255) with a preference for cleaving the amino acid sequence X-I-E-G-R-/X (SEQ ID NO: 88), Collagenase (Chinery et al. (1993) *Eur.J.Biochem.*, Vol 212 (2) pp. 557-553) with a preference for cleaving the amino acid sequence P-X-/G-P-X-X (SEQ ID NO: 89), Thrombin
35 (Rahman et al. (1992) *Cell.Mol.Biol.*, Vol 38 (5) pp. 529-542) with a preference for cleaving the amino acid sequence X-G-V-R-G-P-R-/X (SEQ ID NO: 90), ALP (*Achromobacter lyticus* Lys-specific protease) (Kjeldsen et al., (1996) *Gene*, Vol 170 (1) pp. 107-112) with a preference for

cleaving at Lysine, and the C-component protease from *Bacillus licheniformis* cleaving at Glu (Kakudo et al. (1992) *J.Biol.Chem.*, Vol 267 (33) pp. 23782-23788). Digestive proteases are additional useful proteases, in particular trypsin (mentioned above), but also pepsin, chymotrypsin, and pancreas protease. Chymotrypsin may have a preference for cleaving after aromatic amino acids and Leu.

Another preferred method of cleaving a peptide at a specific target site is by using chemical compounds such as cyanogen-bromide which cleaves X-M-/X or hydroxylamine which cleaves S-N-/G-X (SEQ ID NO: 91) (Current protocols in Molecular Biology. John Wiley and Sons, 1995; Harwood, C. R., and Cutting, S. M.(eds.)).

A still further specific cleavage method is available for D-/P (Asp-Pro) peptide bonds, which can be cleaved by treatment with a weak acid (e.g. pH 2-3) at a suitable temperature, for a suitable time period. Examples of suitable temperatures are 40, 50, 60, 70, or 80°C, and examples of suitable time periods are from a few minutes to a few hours, e.g. ¼ hour to 5 hours, ½ hour to 2½ hours, 1 hour to 3 hours, 1½ hours to 2½ hours.

At nucleotide level, nucleotide sequences corresponding to the above cleavage linkers, as well as to the below peptide protection domains, are of course easily deduced by the person skilled in the art by reference to the genetic code. The nucleotide sequences can also be optimized for the codon usage of the host cell in question, as is well known in the art.

20 **Protection Peptides**

The present invention also relates to the use, in the recombinant expression of antimicrobial peptides, of a so-called quenching domain, or protection peptide, or protection domain, which is characterized in that at least 50% of its component amino acid residues are E and/or D. The purpose of such protection domain is to temporarily inactivate the antimicrobial peptide, in case it would be inhibiting the growth of the host cell. Once sufficient quantities of the peptide have been produced, the protection peptide can be cleaved off as described further below, thus re-activating the antimicrobial peptide. The protection peptide is preferably synthetic (artificial).

In particular embodiments, at least 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% of the amino acid residues comprised in the protection peptide are D and/or E. In a further particular embodiment, the complete amino acid sequence of the protection peptide consists of the amino acid residues D and/or E. In a still further particular embodiment, the protection peptide consists of at least one of the amino acid residues D and/or E, and, optionally, a cleavage linker.

In particular, or alternative, embodiments of this aspect of the invention: (1) The number of D and/or E amino acid residues in the protection peptide is higher than the number

of R and/or K residues; (2) the protection peptide does not contain any C residues; (3) the number of amino acid residues in the protection peptide is lower than the number of amino acid residues in the antimicrobial peptide; and/or (4) the protection peptide is not an inhibitor of bacterial proteases.

5 In a particular embodiment, the protection peptide designates that part of the expressed fusion product which is not the antimicrobial agent, and which is not the signal peptide part, if any. In other particular embodiments, the protection peptide is a stretch of amino acids close to the antimicrobial peptide. The length of the protection peptide is described in more detail below. The protection peptide and the antimicrobial peptide may be
10 separated by a stretch of amino acids of up to 5, up to 8, up to 10, up to 12, up to 15, up to 20, up to 25, or up to 30 amino acids.

The nucleic acid sequence encoding the peptide protection domain may be upstream or downstream of the antimicrobial peptide encoding nucleic acid sequence. In further aspects hereof, the invention relates to a nucleic acid construct comprising a first nucleic acid
15 sequence encoding an antimicrobial peptide, and a second nucleic acid sequence encoding a peptide protection domain as defined above; as well as a recombinant host cell comprising such construct; and a method for production of the antimicrobial peptide by cultivation of the recombinant host cell, and recovery of the peptide, the method optionally comprising the step of cleaving the peptide protection domain using an appropriate cleavage agent, examples of
20 which are mentioned above.

In particular embodiments of these quenching aspects of the invention, everything what is stated herein in relation to the co-expression aspects of the invention also applies to the quenching aspect. This is so in particular, e.g., in relation to the antimicrobial peptide, the control sequences, the host cells etc. Likewise, everything what is stated herein in relation to
25 the quenching aspects is applicable to the co-expression aspects of the invention.

The protection peptide is typically an oligopeptide or a peptide comprising a number of natural, non-natural or modified amino acids that are linked by peptide bonds. In a particular embodiment the constituent amino acids are natural L-amino acids.

Typically, the protection peptide encompasses, in the alternative consists of, between 1
30 and 100, 1 and 95, 1 and 90, 1 and 85, 1 and 80, 1 and 75, 1 and 70, 1 and 65, 1 and 60, 1 and 55, 1 and 50, 1 and 45, 1 and 40, 1 and 35, 1 and 30, 1 and 25, 1 and 20, 1 and 15, or between 1 and 10 amino acid residues.

In further particular embodiments, the protection peptide encompasses, in the alternative consists of, between 1 and 100, 2 and 100, 3 and 100, 4 and 100, 5 and 100, 6 and
35 100, 7 and 100, 8 and 100, 9 and 100, or 10 and 100 amino acid residues.

In additional particular embodiments, the protection peptide encompasses, in the alternative consists of, between 1 and 100, 2 and 90, 3 and 80, 4 and 70, 5 and 60, 5 and 50, 5 and 40, 5 and 35, 5 and 30, 5 and 25, or between 5 and 20 amino acid residues.

These are non-limiting examples of protection peptides of the invention (in the conventional direction, N-terminal first): E, D, ED, DE, DDE, EED, DED, EDE, DDEEE (SEQ ID NO: 92), DDDEE (SEQ ID NO: 93), DDDDE (SEQ ID NO: 94), EEDDE (SEQ ID NO: 95), DDEED (SEQ ID NO: 96), EDEDE (SEQ ID NO: 97), DDDEEE (SEQ ID NO: 98), DEDEDE (SEQ ID NO: 99), and EEDDEE (SEQ ID NO: 100).

In a particular embodiment, the protection peptide is selected from amongst the following: DP, DDDDDP (SEQ ID NO: 101), EEEEEEDP (SEQ ID NO: 102), E, DE, DDE, DDDE (SEQ ID NO: 103), DDDDE (SEQ ID NO: 94), DEDEDEDP (SEQ ID NO: 104), DDDGGEEEGGDDDP (SEQ ID NO: 105), and DDDGGDDPPDDDE (SEQ ID NO: 106).

Those of the above protection peptides which contain E are by the way also cleavable linkers per se, because e.g. the C-component protease from *Bacillus licheniformis* will cleave at the carboxy-terminal side of the E.

Those of the above protection peptides which encompass DP are cleavable by weak acids, see above.

In the alternative, or in addition, these protection peptides can be combined with any suitable cleavage linker to enable their post-productional separation from the antimicrobial peptide.

The table below shows for selected examples of protection peptides how to calculate the percentage of D and/or E residues.

Protection Peptide	Number of amino acids	Number of D/E residues	Percentage of D/E residues
DP	2	1	50
DDDDDP (SEQ ID NO: 101)	6	5	83
EEEEEDP (SEQ ID NO: 102)	7	6	86
DDDE (SEQ ID NO: 94)	5	5	100
DEDEDEDP (SEQ ID NO: 104)	8	7	88
DDGGEEEGGDDDP (SEQ ID NO: 105)	14	9	64
DDGGDDPPDDDE (SEQ ID NO: 106)	14	10	71

The protection peptides of the invention may be identified by a) providing a peptide protection candidate comprising at least one D and/or E; b) preparing a DNA construct

comprising a first DNA sequence encoding the peptide protection candidate and a second DNA sequence encoding an antimicrobial peptide; c) transforming a host cell with the DNA construct of b) and cultivating the transformed host cell to obtain expression of the DNA construct; d) estimating viability of the transformed host cell and/or yield of antimicrobial peptide; and e) identifying a peptide protection candidate which when used in a DNA construct according to step b), for transformation of a host cell according to step c), results in an increased viability of the host cell, and/or an increased yield of antimicrobial peptide, when estimated according to step d).

The viability of the transformed host cell may be measured as is well-known in the art, e.g. by measuring optical density (OD) at 450 or 600 nm, for example at 450 nm. The yield of the antimicrobial agent, for example the antimicrobial peptide, may be estimated on a coomassie-stained SDS gel, e.g. by looking for bands of the expected molecular weight and, if desired, also band intensity (see Example 5).

15 **Expression Vectors**

The present invention also relates to recombinant expression vectors comprising a first nucleic acid sequence encoding an antimicrobial agent; a second nucleic acid sequence encoding an enzyme; a promoter; and transcriptional and translational stop signals.

The various nucleic acid and control sequences described above may be joined together to produce a recombinant expression vector which may include one or more convenient restriction sites to allow for insertion or substitution of the nucleic acid sequences encoding the enzyme and the antimicrobial agent at such sites. Alternatively, the nucleic acid sequences of the present invention may be expressed by inserting the nucleic acid sequences or a nucleic acid construct comprising the sequences into an appropriate vector for expression. In creating the expression vector, the coding sequences are located in the vector so that the coding sequences are operably linked with the appropriate control sequences for expression.

The recombinant expression vector may be any vector (e.g., a plasmid or virus) which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the nucleic acid sequence. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vectors may be linear or closed circular plasmids.

The vector may be an autonomously replicating vector, i.e., a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one which, when introduced into the host cell, is integrated into the genome

and replicated together with the chromosome(s) into which it has been integrated. Furthermore, a single vector or plasmid or two or more vectors or plasmids which together contain the total DNA to be introduced into the genome of the host cell, or a transposon may be used.

5 The vectors of the present invention preferably contain one or more selectable markers which permit easy selection of transformed cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like. Examples of bacterial selectable markers are the *dal* genes from
10 *Bacillus subtilis* or *Bacillus licheniformis*, or markers which confer antibiotic resistance such as ampicillin, kanamycin, chloramphenicol or tetracycline resistance. Suitable markers for yeast host cells are *ADE2*, *HIS3*, *LEU2*, *LYS2*, *MET3*, *TRP1*, and *URA3*. Selectable markers for use in a filamentous fungal host cell include, but are not limited to, *amdS* (acetamidase), *argB* (ornithine carbamoyltransferase), *bar* (phosphinothricin acetyltransferase), *hygB* (hygromycin phosphotransferase), *niaD* (nitrate reductase), *pyrG* (orotidine-5'-phosphate decarboxylase),
15 *sC* (sulfate adenylyltransferase), *trpC* (anthranilate synthase), as well as equivalents thereof. Preferred for use in an *Aspergillus* cell are the *amdS* and *pyrG* genes of *Aspergillus nidulans* or *Aspergillus oryzae* and the *bar* gene of *Streptomyces hygrosopicus*.

 The vectors of the present invention preferably contain an element(s) that permits stable integration of the vector into the host cell's genome or autonomous replication of the
20 vector in the cell independent of the genome.

 For integration into the host cell genome, the vector may rely on the nucleic acid sequence encoding the enzyme, or the nucleic acid sequence encoding the antimicrobial agent, or any other element of the vector for stable integration of the vector into the genome by homologous or nonhomologous recombination. Alternatively, the vector may contain
25 additional nucleic acid sequences for directing integration by homologous recombination into the genome of the host cell. The additional nucleic acid sequences enable the vector to be integrated into the host cell genome at a precise location(s) in the chromosome(s). To increase the likelihood of integration at a precise location, the integrational elements should preferably contain a sufficient number of nucleic acids, such as 100 to 1,500 base pairs,
30 preferably 400 to 1,500 base pairs, and most preferably 800 to 1,500 base pairs, which are highly homologous with the corresponding target sequence to enhance the probability of homologous recombination. The integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell. Furthermore, the integrational elements may be non-encoding or encoding nucleic acid sequences. On the
35 other hand, the vector may be integrated into the genome of the host cell by non-homologous recombination.

For autonomous replication, the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question. Examples of bacterial origins of replication are the origins of replication of plasmids pBR322, pUC19, pACYC177, and pACYC184 permitting replication in *E. coli*, and pUB110, pE194, pTA1060, and pAM β 1 permitting replication in *Bacillus*. Examples of origins of replication for use in a yeast host cell are the 2 micron origin of replication, ARS1, ARS4, the combination of ARS1 and CEN3, and the combination of ARS4 and CEN6. The origin of replication may be one having a mutation which makes its functioning temperature-sensitive in the host cell (see, e.g., Ehrlich, 1978, Proceedings of the National Academy of Sciences USA 75: 1433).

More than one copy of a nucleic acid sequence of the present invention may be inserted into the host cell to increase production of the gene product. An increase in the copy number of the nucleic acid sequence can be obtained by integrating at least one additional copy of the sequence into the host cell genome or by including an amplifiable selectable marker gene with the nucleic acid sequence where cells containing amplified copies of the selectable marker gene, and thereby additional copies of the nucleic acid sequence, can be selected for by cultivating the cells in the presence of the appropriate selectable agent.

The procedures used to ligate the elements described above to construct the recombinant expression vectors of the present invention are well known to one skilled in the art (see, e.g., Sambrook et al., 1989, supra).

Host Cells

The present invention relates to recombinant host cells comprising a first nucleic acid sequence encoding an antimicrobial agent, and a second heterologous nucleic acid sequence encoding an enzyme.

These host cells are advantageously used in the recombinant production of the antimicrobial agent and the enzyme. At least one vector comprising the corresponding nucleic acid sequences is introduced into a host cell, so that the vector(s) is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector as described earlier. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication. Generally, the choice of a host cell will to a large extent depend upon the gene encoding the antimicrobial agent, and/or on the gene encoding the enzyme and its source. For example, a host cell may be selected which is not affected, or affected to a very limited extent only, by the antimicrobial activity of the agent. In the alternative, the host cell is protected from the antimicrobial activity by provisionally or temporarily inactivating (quenching) the peptide. Still further, generally, a fungal enzyme is preferably expressed in a fungal host cell, and a bacterial enzyme in a bacterial host cell.

The host cell may be a unicellular microorganism, e.g., a prokaryote, or a non-unicellular microorganism, e.g., a eukaryote.

Useful unicellular cells are bacterial cells such as gram positive bacteria including, but not limited to, a *Bacillus* cell, or a *Streptomyces* cell, or cells of lactic acid bacteria; or gram
5 negative bacteria such as *E. coli* and *Pseudomonas* sp. Lactic acid bacteria include, but are not limited to, species of the genera *Lactococcus*, *Lactobacillus*, *Leuconostoc*, *Streptococcus*, *Pediococcus*, and *Enterococcus*.

The introduction of a vector into a bacterial host cell may, for instance, be effected by protoplast transformation (see, e.g., Chang and Cohen, 1979, *Molecular General Genetics*
10 168: 111-115), using competent cells (see, e.g., Young and Spizizin, 1961, *Journal of Bacteriology* 81: 823-829, or Dubnau and Davidoff-Abelson, 1971, *Journal of Molecular Biology* 56: 209-221), electroporation (see, e.g., Shigekawa and Dower, 1988, *Biotechniques* 6: 742-751), or conjugation (see, e.g., Koehler and Thorne, 1987, *Journal of Bacteriology* 169: 5771-5278).

15 The host cell may be a eukaryote, such as a non-human animal cell, an insect cell, a plant cell, or a fungal cell.

In one particular embodiment, the host cell is a fungal cell. "Fungi" as used herein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota (as defined by Hawksworth et al., In, *Ainsworth and Bisby's Dictionary of The Fungi*, 8th edition, 1995,
20 CAB International, University Press, Cambridge, UK) as well as the Oomycota (as cited in Hawksworth et al., 1995, supra, page 171) and all mitosporic fungi (Hawksworth et al., 1995, supra).

In another particular embodiment, the fungal host cell is a yeast cell. "Yeast" as used herein includes ascosporogenous yeast (Endomycetales), basidiosporogenous yeast, and
25 yeast belonging to the Fungi Imperfecti (Blastomycetes). Since the classification of yeast may change in the future, for the purposes of this invention, yeast shall be defined as described in *Biology and Activities of Yeast* (Skinner, F.A., Passmore, S.M., and Davenport, R.R., eds, Soc. App. Bacteriol. Symposium, Series No. 9, 1980).

The yeast host cell may be a *Candida*, *Hansenula*, *Kluyveromyces*, *Pichia*,
30 *Saccharomyces*, *Schizosaccharomyces*, or *Yarrowia* cell.

The fungal host cell may be a filamentous fungal cell. "Filamentous fungi" include all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth et al., 1995, supra). The filamentous fungi are characterized by a mycelial wall composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative
35 growth is by hyphal elongation and carbon catabolism is obligately aerobic. In contrast, vegetative growth by yeasts such as *Saccharomyces cerevisiae* is by budding of a unicellular thallus and carbon catabolism may be fermentative.

Examples of filamentous fungal host cells are cells of species of, but not limited to, Acremonium, Aspergillus, Fusarium, Humicola, Mucor, Myceliophthora, Neurospora, Penicillium, Thielavia, Tolypocladium, or Trichoderma.

Fungal cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known *per se*. Suitable procedures for transformation of Aspergillus host cells are described in EP 238 023 and Yelton et al., 1984, Proceedings of the National Academy of Sciences USA 81: 1470-1474. Suitable methods for transforming Fusarium species are described by Malardier et al., 1989, Gene 78: 147-156 and WO 96/00787. Yeast may be transformed using the procedures described by Becker and Guarente, In Abelson, J.N. and Simon, M.I., editors, Guide to Yeast Genetics and Molecular Biology, Methods in Enzymology, Volume 194, pp 182-187, Academic Press, Inc., New York; Ito et al., 1983, Journal of Bacteriology 153: 163; and Hinnen et al., 1978, Proceedings of the National Academy of Sciences USA 75: 1920.

In a particular embodiment the host cell is a microbial host cell, which includes bacterial host cells and fungal host cells, as defined above.

Methods of Production

The present invention also relates to methods for producing an enzyme and an antimicrobial agent, the method comprising (a) cultivating a host cell of the invention under conditions conducive for production of the enzyme and the antimicrobial agent; and (b) recovering the enzyme and/or the antimicrobial agent.

In the production methods of the present invention, the cells are cultivated in a nutrient medium suitable for production of the enzyme and the antimicrobial agent using methods known in the art. For example, the cell may be cultivated by shake flask cultivation, small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the polypeptide to be expressed and/or isolated. The cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art. Suitable media are available from commercial suppliers or may be prepared according to published compositions (e.g., in catalogues of the American Type Culture Collection).

If the enzyme and the antimicrobial agent are secreted into the nutrient medium, they can be recovered directly from the medium. If they are not secreted, they can be recovered from cell lysates.

The enzyme may be detected using methods known in the art that are specific for the enzyme in question. These detection methods may include use of specific antibodies, formation of an enzyme-product, or disappearance of an enzyme-substrate. For example, an

enzyme assay may be used to determine the activity of the enzyme as described herein. The antimicrobial agent may be detected using antibodies directed against one or more epitopes on the peptide, or the peptide may be detected using antimicrobial activity.

5 The following are examples of products commonly referred to above as "the enzyme and the peptide":

a) A fusion product, which briefly may be designated AMP-ENZ, however, as explained above the order of AMP and ENZ can be reversed, and the number and kind of individual AMP and ENZ entities can vary;

10 b) AMP and ENZ as separate entities (varying numbers, varying kinds as explained above);

c) AMP-Q and ENZ as separate entities, the expression AMP-Q designating the attachment of a protective (Quenching) domain to the AMP molecule (again, varying numbers, varying kinds, as explained above); and

15 d) A fusion product AMP-Q-ENZ (varying numbers, kinds, relative position etc. as explained above).

As desired, only the enzyme may be recovered, only the antimicrobial agent may be recovered, or both products may be recovered.

20 These products may be recovered by methods known in the art. For example, they may be recovered by conventional procedures including, but not limited to, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation.

25 The products may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing), differential solubility (e.g., ammonium sulfate precipitation), SDS-PAGE, or extraction (see, e.g., Protein Purification, J.C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).

When the enzyme and the antimicrobial agent are expressed as two distinct products, they may be separated, e.g. by gel filtration, and the further purification of one or both of these products, if desired or required, may then follow conventional routes as described above.

30 In a particular embodiment of the method for producing the enzyme and the antimicrobial agent, the method comprises a step of cleaving the fusion product, i.e. separating the antimicrobial agent and enzyme parts of the fusion product. This can be done using appropriate cleavage agents, examples of which are described above. The cleavage step can be performed before, during or after the recovery procedure, or the cleavage can be
35 done at any time after the recovery, e.g. by an end-user or by a purchaser of the fusion product, e.g. just prior to the intended end-use of the product, or as a step in a procedure of preparing an intermediate product, e.g. an animal feed additive.

In another embodiment, in connection with the use of the fusion product in animal feed, the fusion product is not cleaved at all before intake by the animal, but digestive proteases and/or chemical/physical conditions in the digestive system of the animal in question takes care of the cleavage, and the active enzyme and antimicrobial agent molecules are accordingly only released in vivo, upon digestion by an animal. Digestive proteases are examples of appropriate cleavage agents for such embodiment.

In a still further embodiment of the method of the invention, the protection peptide, or a part thereof, is separated from the antimicrobial peptide part in a cleavage step, that may be the same as the cleavage step described above, or an a separate, additional cleavage step.

A further particular embodiment of the method of the invention comprises the step of adding additional enzyme and/or antimicrobial agent molecules to the product resulting from the recovery procedure. This could be with a view to obtaining a product with a desired molar ratio between the antimicrobial agent(s) and the enzyme(s).

15 **Plants**

The present invention also relates to a transgenic plant, plant part, or plant cell which has been transformed with nucleic acid sequences encoding an enzyme and an antimicrobial agent so as to express and produce these in recoverable quantities. The enzyme and the antimicrobial agent may be recovered from the plant or plant part. Alternatively, the plant or plant part containing these products may be used as such for improving the quality of a food or feed, e.g., improving nutritional value, palatability, and rheological properties, or to destroy an antinutritive factor.

In a particular embodiment, the enzyme and the antimicrobial agent are targeted to the endosperm storage vacuoles in seeds. This can be obtained by synthesizing it as a precursor with a suitable signal peptide, see Horvath et al in PNAS, Feb. 15, 2000, vol. 97, no. 4, p. 1914-1919.

The transgenic plant can be dicotyledonous (a dicot) or monocotyledonous (a monocot) or engineered variants thereof. Examples of monocot plants are grasses, such as meadow grass (blue grass, *Poa*), forage grass such as *festuca*, *lolium*, temperate grass, such as *Agrostis*, and cereals, e.g., wheat, oats, rye, barley, rice, sorghum, triticale (stabilized hybrid of wheat (*Triticum*) and rye (*Secale*), and maize (corn). Examples of dicot plants are tobacco, legumes, such as sunflower (*Helianthus*), cotton (*Gossypium*), lupins, potato, sugar beet, pea, bean and soybean, and cruciferous plants (family *Brassicaceae*), such as cauliflower, rape seed, and the closely related model organism *Arabidopsis thaliana*. Low-phytate plants as described e.g. in US patent no. 5,689,054 and US patent no. 6,111,168 are examples of engineered plants.

Examples of plant parts are stem, callus, leaves, root, fruits, seeds, and tubers. Also specific plant tissues, such as chloroplast, apoplast, mitochondria, vacuole, peroxisomes, and cytoplasm are considered to be a plant part. Furthermore, any plant cell, whatever the tissue origin, is considered to be a plant part.

5 Also included within the scope of the present invention are the progeny of such plants, plant parts and plant cells.

The transgenic plant or plant cell expressing an antimicrobial agent and an enzyme of the present invention may be constructed in accordance with methods known in the art. Briefly, the plant or plant cell is constructed by incorporating one or more expression
10 constructs encoding the enzyme and the antimicrobial agent into the plant host genome and propagating the resulting modified plant or plant cell into a transgenic plant or plant cell.

Conveniently, the expression construct is a nucleic acid construct which comprises a nucleic acid sequence encoding the enzyme and a nucleic acid sequence encoding the antimicrobial agent, operably linked with appropriate regulatory sequences required for
15 expression thereof in the plant or plant part of choice. Furthermore, the expression construct may comprise a selectable marker useful for identifying host cells into which the expression construct has been integrated and DNA sequences necessary for introduction of the construct into the plant in question (the latter depends on the DNA introduction method to be used).

The choice of regulatory sequences, such as promoter and terminator sequences and
20 optionally signal or transit sequences are determined, for example, on the basis of when, where, and how the antimicrobial agent and the enzyme are desired to be expressed. For instance, the expression of the genes may be constitutive or inducible, or may be developmental, stage or tissue specific, and the gene products may be targeted to a specific tissue or plant part such as seeds or leaves. Regulatory sequences are, for example,
25 described by Tague et al., 1988, *Plant Physiology* 86: 506.

For constitutive expression, the 35S-CaMV promoter may be used (Franck et al., 1980, *Cell* 21: 285-294). Organ-specific promoters may be, for example, a promoter from storage sink tissues such as seeds, potato tubers, and fruits (Edwards & Coruzzi, 1990, *Ann. Rev. Genet.* 24: 275-303), or from metabolic sink tissues such as meristems (Ito et al., 1994,
30 *Plant Mol. Biol.* 24: 863-878), a seed specific promoter such as the glutelin, prolamin, globulin, or albumin promoter from rice (Wu et al., 1998, *Plant and Cell Physiology* 39: 885-889), a *Vicia faba* promoter from the legumin B4 and the unknown seed protein gene from *Vicia faba* (Conrad et al., 1998, *Journal of Plant Physiology* 152: 708-711), a promoter from a seed oil body protein (Chen et al., 1998, *Plant and Cell Physiology* 39: 935-941), the storage protein
35 napA promoter from *Brassica napus*, or any other seed specific promoter known in the art, e.g., as described in WO 91/14772. Furthermore, the promoter may be a leaf specific promoter such as the rbcS promoter from rice or tomato (Kyoizuka et al., 1993, *Plant*

Physiology 102: 991-1000, the chlorella virus adenine methyltransferase gene promoter (Mitra and Higgins, 1994, Plant Molecular Biology 26: 85-93), or the aldP gene promoter from rice (Kagaya et al., 1995, Molecular and General Genetics 248: 668-674), or a wound inducible promoter such as the potato pin2 promoter (Xu et al., 1993, Plant Molecular Biology 22: 573-588).

5 A promoter enhancer element may also be used to achieve higher expression of the enzyme and the antimicrobial agent in the plant. For instance, the promoter enhancer element may be an intron which is placed between the promoter and the nucleotide sequence encoding a polypeptide of the present invention. For instance, Xu et al., 1993, supra disclose
10 the use of the first intron of the rice actin 1 gene to enhance expression.

Still further, the codon usage may be optimized for the plant species in question to improve expression (see Horvath et al referred to above).

The selectable marker gene and any other parts of the expression construct may be chosen from those available in the art.

15 The nucleic acid construct is incorporated into the plant genome according to conventional techniques known in the art, including Agrobacterium-mediated transformation, virus-mediated transformation, microinjection, particle bombardment, biolistic transformation, and electroporation (Gasser et al., 1990, Science 244: 1293; Potrykus, 1990, Bio/Technology 8: 535; Shimamoto et al., 1989, Nature 338: 274).

20 Presently, Agrobacterium tumefaciens-mediated gene transfer is the method of choice for generating transgenic dicots (for a review, see Hooykas and Schilperoort, 1992, Plant Molecular Biology 19: 15-38). However it can also be used for transforming monocots, although other transformation methods are generally preferred for these plants. Presently, the method of choice for generating transgenic monocots is particle bombardment (microscopic
25 gold or tungsten particles coated with the transforming DNA) of embryonic calli or developing embryos (Christou, 1992, Plant Journal 2: 275-281; Shimamoto, 1994, Current Opinion Biotechnology 5: 158-162; Vasil et al., 1992, Bio/Technology 10: 667-674). An alternative method for transformation of monocots is based on protoplast transformation as described by Omirulleh et al., 1993, Plant Molecular Biology 21: 415-428.

30 Following transformation, the transformants having incorporated therein the expression construct are selected and regenerated into whole plants according to methods well-known in the art.

The present invention also relates to methods for producing an enzyme and an antimicrobial agent, the method comprising (a) cultivating a transgenic plant or a plant cell
35 comprising the encoding nucleic acid sequences under conditions conducive for production of the antimicrobial agent and the enzyme; and (b) recovering these.

Animals

The present invention also relates to a transgenic, non-human animal and products or elements thereof, examples of which are body fluids such as milk and blood, organs, flesh, and animal cells. Techniques for expressing proteins, e.g. in mammalian cells, are known in the art, see e.g. the handbook Protein Expression: A Practical Approach, Higgins and Hames (eds), Oxford University Press (1999), and the three other handbooks in this series relating to Gene Transcription, RNA processing, and Post-translational Processing. Generally speaking, to prepare a transgenic animal, selected cells of a selected animal are transformed with nucleic acid sequences encoding an enzyme and an antimicrobial agent so as to express and produce these. The agent and the enzyme may be recovered from the animal, e.g. from the milk of female animals, or they may be expressed to the benefit of the animal itself, e.g. to assist the animal's digestion. Examples of animals are mentioned below in the section headed Animal Feed.

To produce a transgenic animal with a view to recovering the antimicrobial agent and the enzyme from the milk of the animal, the encoding nucleic acid sequences may be inserted into the fertilized eggs of an animal in question, e.g. by use of transgene expression vector(s) which comprises a suitable milk protein promoter, and the desired nucleic acid sequences. The transgene expression vector is microinjected into fertilized eggs, and preferably permanently integrated into the chromosome. Once the egg begins to grow and divide, the potential embryo is implanted into a surrogate mother, and animals carrying the transgene are identified. The resulting animal can then be multiplied by conventional breeding. The enzyme and the agent may be purified from the animal's milk, see e.g. Meade, H.M. et al (1999): Expression of recombinant proteins in the milk of transgenic animals, Gene expression systems: Using nature for the art of expression. J. M. Fernandez and J. P. Hoeffler (eds.), Academic Press.

In the alternative, in order to produce a transgenic non-human animal that carries in the genome of its somatic and/or germ cells a nucleic acid sequence including a heterologous transgene construct including transgenes encoding the antimicrobial agent and the enzyme, the transgene may be operably linked to a first regulatory sequence for salivary gland specific expression, as disclosed in WO 00/064247.

Compositions

In a still further aspect, the present invention relates to compositions comprising the fusion product of antimicrobial agent and enzyme, if desired with a protection peptide (such as AMP-(Q)-ENZ), as described above.

These compositions may be prepared in accordance with methods known in the art and may be in the form of a liquid or a dry composition. For instance, they may be in the form

of granulates or microgranulates. The enzyme and the antimicrobial agent to be included in the composition may be stabilized in accordance with methods known in the art.

Examples are given below of preferred uses of the enzyme and the antimicrobial agent of the invention.

5

Animal Feed

The term animal includes all animals, including human beings. Examples of animals are non-ruminants, and ruminants. Ruminant animals include, for example, animals such as sheep, goats, horses, and cattle, e.g. beef cattle, cows, and young calves. In a particular
10 embodiment, the animal is a non-ruminant animal. Non-ruminant animals include mono-gastric animals, e.g. pigs or swine (including, but not limited to, piglets, growing pigs, and sows); poultry such as turkeys, ducks and chicken (including but not limited to broiler chicks, layers); young calves; and fish (including but not limited to salmon, trout, tilapia, catfish and carps; and crustaceans (including but not limited to shrimps and prawns).

15 The term feed or feed composition means any compound, preparation, mixture, or composition suitable for, or intended for intake by an animal.

In the use according to the invention the enzyme and the antimicrobial agent can be fed to the animal before, after, or simultaneously with the diet. The latter is preferred.

20 In a particular embodiment, the enzyme and the antimicrobial agent, in the form in which they are added to the feed, or when being included in a feed additive, are well-defined. Well-defined means that the preparation is at least 50% pure as determined by Size-exclusion chromatography (see Example 12 of WO 01/58275). In other particular embodiments the preparation is at least 60, 70, 80, 85, 88, 90, 92, 94, or at least 95% pure as determined by this method.

25 A well-defined preparation is advantageous. For instance, it is much easier to dose correctly to the feed a preparation of enzyme and antimicrobial agent that is essentially free from interfering or contaminating other ingredients. The term dose correctly refers in particular to the objective of obtaining consistent and constant results, and the capability of optimising dosage based upon the desired effect.

30 For the use in animal feed, however, the enzyme and the antimicrobial agent need not be that pure; it may e.g. include additional enzymes and/or additional agents.

The preparation can be (a) added directly to the feed (or used directly in a treatment process of proteins), or (b) it can be used in the production of one or more intermediate compositions such as feed additives or premixes that is subsequently added to the feed (or
35 used in a treatment process). The degree of purity described above refers to the purity of the original enzyme and antimicrobial agent preparation, whether used according to (a) or (b) above.

The animal feed usually comprises vegetable proteins, e.g. derived from legumes and cereals, for example materials from plants of the families Fabaceae (Leguminosae), Cruciferae, Chenopodiaceae, and Poaceae, such as soy bean meal, lupin meal and rapeseed meal. The feed may also comprise an animal protein, such as meat and bone meal,
5 and/or fish meal.

In a particular embodiment, the vegetable protein derives from one or more plants of the family Fabaceae, e.g. soybean, lupine, pea, or bean.

In another particular embodiment, the vegetable protein derives from one or more plants of the family Chenopodiaceae, e.g. beet, sugar beet, spinach or quinoa.

10 Other examples of vegetable protein sources are rapeseed, sunflower seed, cotton seed, and cabbage.

Soybean is a preferred vegetable protein source.

Other examples of vegetable protein sources are cereals such as barley, wheat, rye, oat, maize (corn), rice, triticale, and sorghum.

15 In a particular embodiment, the enzyme and the antimicrobial agent improve the nutritional value of an animal feed, viz. e.g. the growth rate and/or the weight gain and/or the feed conversion (i.e. the weight of ingested feed relative to weight gain).

The enzyme and the antimicrobial agent can be added to the feed in any form, be it as a relatively pure product, or in admixture with other components intended for addition to animal
20 feed, i.e. in the form of animal feed additives, such as the so-called pre-mixes for animal feed.

In a further aspect the present invention relates to compositions for use in animal feed, such as animal feed, and animal feed additives, e.g. premixes.

Apart from the enzyme and the antimicrobial agent of the invention, the animal feed additives of the invention contain at least one fat-soluble vitamin, and/or at least one water
25 soluble vitamin, and/or at least one trace mineral, and/or optionally at least one macro mineral.

Further, optional, feed-additive ingredients are colouring agents, e.g. carotenoids such as beta-carotene, astaxanthin, and lutein; aroma compounds; stabilisers; polyunsaturated fatty acids; reactive oxygen generating species.

Usually fat- and water-soluble vitamins, as well as trace minerals form part of a so-called
30 premix intended for addition to the feed, whereas macro minerals are usually separately added to the feed. Either of these composition types, when enriched with the enzyme and the antimicrobial agent of the invention, is an animal feed additive of the invention.

The following are non-exclusive lists of examples of these components:

35 Examples of fat-soluble vitamins are vitamin A, vitamin D3, vitamin E, and vitamin K, e.g. vitamin K3.

Examples of water-soluble vitamins are vitamin B12, biotin and choline, vitamin B1, vitamin B2, vitamin B6, niacin, folic acid and panthothenate, e.g. Ca-D-panthothenate.

Examples of trace minerals are manganese, zinc, iron, copper, iodine, selenium, and cobalt.

Examples of macro minerals are calcium, phosphorus and sodium.

5 Examples of polyunsaturated fatty acids are C18, C20 and C22 polyunsaturated fatty acids, such as arachidonic acid, docosohexaenoic acid, eicosapentaenoic acid and gamma-linoleic acid.

Examples of reactive oxygen generating species are chemicals such as perborate, persulphate, or percarbonate; and enzymes such as an oxidase, an oxygenase or a syntethase.

10 An animal feed composition according to the invention has a crude protein content of 50-800 g/kg, and furthermore comprises at least one enzyme and antimicrobial agent of the invention.

Crude protein is calculated as nitrogen (N) multiplied by a factor 6.25, i.e. Crude protein (g/kg) = N (g/kg) x 6.25. The nitrogen content is determined by the Kjeldahl method
15 (A.O.A.C., 1984, Official Methods of Analysis 14th ed., Association of Official Analytical Chemists, Washington DC).

In a particular embodiment, the animal feed composition of the invention contains at least one vegetable protein or protein source as defined above. It may also contain animal protein, such as Meat and Bone Meal, and/or Fish Meal, typically in an amount of 0-25%.

20 In still further particular embodiments, the animal feed composition of the invention contains 0-80% maize; and/or 0-80% sorghum; and/or 0-70% wheat; and/or 0-70% Barley; and/or 0-30% oats; and/or 0-40% soybean meal; and/or 0-10% fish meal; and/or 0-20% whey.

Animal diets can e.g. be manufactured as mash feed (non-pelleted) or pelleted feed. Typically, the milled feed-stuffs are mixed and sufficient amounts of essential vitamins and
25 minerals are added according to the specifications for the species in question. The enzyme and the antimicrobial agent can be added as solid or liquid formulations. For example, a solid formulation is typically added before or during the mixing step; and a liquid preparation is typically added after the pelleting step. The enzyme and the antimicrobial agent may also be incorporated in a feed additive or premix.

30 These are particular embodiments of the invention:

A recombinant host cell comprising at least one nucleic acid construct that comprises i) a first nucleic acid sequence encoding a peptide, said peptide a) encompassing no more than 100 amino acids, and b) having antimicrobial activity; and ii) a second nucleic acid sequence encoding an enzyme; preferably the recombinant host cell comprises a first nucleic acid
35 construct, and a second nucleic acid construct, wherein i) the first nucleic acid construct comprises the first nucleic acid sequence encoding the peptide; and ii) the second nucleic acid construct comprises the second nucleic acid sequence encoding the enzyme; more preferably

the recombinant host cell comprises a nucleic acid construct comprising i) the first nucleic acid sequence encoding the peptide, and ii) the second nucleic acid sequence encoding the enzyme.

5 A nucleic acid construct comprising a first nucleic acid sequence encoding a peptide as defined above, and a second nucleic acid sequence encoding an enzyme as defined in claim 1, operably linked to one or more control sequences that direct the expression of the enzyme and the peptide in a suitable expression host.

10 A method for producing the enzyme and the peptide as defined above, the method comprising: (a) cultivating the recombinant host cell as described above to produce a supernatant comprising the enzyme and the peptide; and (b) recovering the enzyme and/or the peptide.

A fusion product comprising an enzyme, an antimicrobial peptide of no more than 100 amino acids, and a cleavable linker.

15 An animal feed additive comprising (a) at least one fusion product as defined above, (b) at least one fat soluble vitamin, and/or (c) at least one water soluble vitamin, and/or (d) at least one trace mineral.

An animal feed composition having a crude protein content of 50 to 800 g/kg and comprising at least one fusion product as defined above.

20 A transgenic plant, or plant part, capable of expressing the enzyme and the peptide as defined above.

A transgenic, non-human animal, or products, or elements thereof, capable of expressing the enzyme and the peptide as defined above.

Use of the fusion product as defined above in animal feed.

25 Use of co-expression of the peptide and the enzyme as defined above as a tool to improve the yield of the peptide and/or to improve overall production economy.

In the recombinant expression of an antimicrobial peptide encompassing no more than 100 amino acids, the use of a peptide protection domain, wherein at least 50% of the amino acid residues comprised in the peptide protection domain are D and/or E; wherein preferably the peptide protection domain encompasses between 1 and 100 amino acid residues.

30 A peptide, preferably isolated, wherein at least 50% of the amino acid residues are D (Asp) and/or E (Glu) and wherein the peptide has peptide protection activity, as well as the corresponding nucleic acid.

35 A method for identifying a protection peptide comprising at least one D (Asp) and/or E (Glu), the method comprising: a) providing a library of peptide protection candidates comprising at least one D and/or E; b) preparing a library of DNA constructs comprising a first DNA sequence encoding a member of the library of peptide protection candidate and a second DNA sequence encoding an antimicrobial peptide; c) transforming host cells with the

library of DNA constructs of b) and cultivating the transformed host cells to obtain expression of the DNA constructs; d) estimating, and/or analyzing, viability of the transformed host cells, and/or estimating, and/or analyzing, the yield of antimicrobial peptide; and e) identifying peptide protection candidates which when used in a DNA construct according to step b), for transformation of a host cell according to step c), results in an increased viability of the host cell, and/or an increased yield of antimicrobial peptide, when estimated, and/or analyzed, according to step d); as well as a protection peptide obtainable, and/or obtained, by such method.

The invention described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed, since these embodiments are intended as illustrations of several aspects of the invention. Any equivalent embodiments are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. In the case of conflict, the present disclosure including definitions will control.

Various references are cited herein, the disclosures of which are incorporated by reference in their entireties.

Examples

Generally, reference is made to Sambrook, Fritsch, and Maniatis, 1989, for the various standard protocols employed in the present experimental part.

Example 1: Assay for antimicrobial activity

This assay is particularly useful for assaying the antimicrobial activity of Novispirin and PR39. It is based on the protocol of Lehrer et al. (1991), J. Immunol. Methods 137: 167-173.

The selected target bacteria, e.g. E.coli ATCC 10536, or B. subtilis ATCC 6633 (10^6 colony forming units (CFU)) were added to 10 ml of underlay agarose (1% low electro-osmosis agarose, 0.03% Trypticase soy broth, 10 mM sodium phosphate, pH 7.4, 37 degrees C). The suspension was solidified in an INTEGRID Petri Dish (Becton Dickinson Labware, NJ). A 3 mm Gel Puncher was used to punch holes in the underlay agarose (Amersham Pharmacia Biotech, Sweden). Samples expected to exhibit antimicrobial activity were added to the holes and incubated at 37 degrees C for 3 hours. An overlay (LB media, 7.5% Agar) was poured on top and the plate was incubated overnight at 37 degrees C. Antimicrobial activity was seen as clearing zones around the wells. Living cells were counterstained by adding 10 ml, 0.2 mM MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Thiazolyl blue).

Example 2: Use of quenching domains for the expression of antimicrobial agents as inclusion bodies in E. coli

PR39 is a proline- and arginine-rich peptide which was originally isolated from pig intestine on the basis of antimicrobial activity (Agerberth, B. et al., Eur. J. Biochem. 202, 849-54 (1991)). The mature form of PR39 is composed of the following 39 amino acids:
5 RRRPRPPYLPRPRPPFFPPRLPPRIPPGFPPRFPPRFP (SEQ ID NO: 65)

Expression of antimicrobial peptides like e.g. PR39 in inclusion bodies has proven difficult for reasons that are not completely understood. In this experiment we evaluate the effect on the expression level of using various peptide protection domains of the invention.

10 The following fusion constructs were made in the pET31b+ expression vector system (commercially available from NOVAGEN):

PHM300: KSI-NG-PR39

PHM370: KSI-DP-PR39

PHM360: KSI-DDDDDP(SEQ ID NO: 101)-PR39 (SEQ ID NO: 65)

15 PHM350: KSI-EEEEEDP(SEQ ID NO: 102)-PR39 (SEQ ID NO: 65)

KSI is an insoluble fragment of Ketosteroid Isomerase that is known to promote the expression as insoluble inclusion bodies of the peptide or protein of interest. KSI forms part of the pET31b+ expression vector system.

20 PR39 designates the amino acid sequence of the mature PR39 peptide (SEQ ID NO: 65).

DP (Asp-Pro), DDDDDP (Asp-Asp-Asp-Asp-Asp-Pro) (SEQ ID NO: 101), and EEEEEEDP (Glu-Glu-Glu-Glu-Glu-Asp-Pro) (SEQ ID NO: 102) are examples of peptide protection domains of the present invention.

25 NG (Asn-Gly) is an example of a linker which is not a protection domain of the invention.

Recombinant plasmids were transformed into Escherichia coli strain BL21-DE3 (forms part of the pET31b+ kit) and the expression of PR39 was evaluated through IPTG induction and SDS-PAGE. The results clearly showed increased expression from constructs PHM 370, 360 and 350 as compared to PHM300. Still further, the expression levels were clearly
30 increased by construct PHM350 as compared to constructs PHM360 and PHM370, and by construct PHM360 as compared to construct PHM370.

After expression, the resulting fusion products can be cleaved by treatment with a weak acid (cleavage site: D-/P), whereby the antimicrobial peptide regain its antimicrobial activity.

35

Example 3: Use of quenching domains in the expression of antimicrobial agents in an E. coli Suicide Expression System

This example makes use of the Suicide Expression System (SES) as described in WO 00/73433, see in particular Example 1.

The host cell used is *Escherichia coli* TOP10 which is commercially available from Invitrogen (araBAD⁻, araEFGH⁺).

5 Plasmids of series pHH (using plasmid pBAD/gIII A) allow for the export of the antimicrobial peptides to the periplasmic space of *E. coli*, from where the peptides are allowed to interact with the cellular membranes. Plasmid pBAD/gIII A is commercially available from Invitrogen. It is a pUC-derived expression vector designed for tightly regulated, recombinant protein expression in *E. coli*. This plasmid allows the cloning of peptides and proteins toxic to
10 *E. coli*, as no expression of the recombinant peptides occurs in the absence of inducer in the growth medium. However, transcription and hence peptide synthesis, can be extensively induced. In series pHH, the gene III signal sequence in pBAD/gIII A is located in front of the inducible promoter in order to mediate secretion of the peptide/protein in question. Gene III encodes pIII, one of the minor capsid proteins from the filamentous phage fd. pIII is
15 synthesized with an 18 amino acid, N-terminal signal sequence, and requires the bacterial Sec system for insertion into the membrane. The signal sequence is removed after crossing the inner membrane, thus leaving the mature peptide. An NcoI restriction site immediately succeeds the signal sequence cleavage site.

The gene(s) encoding the antimicrobial peptide(s) are inserted in plasmids of the pHH series as NcoI-XbaI fragments. In case of PR39 this results in an introduction of amino acids
20 MA at the N-terminus of the peptide (CCATGG). The natural codon usage is retained.

Five different N-terminal extensions to PR39 were constructed, viz.: E, DE, DDE, DDDE (SEQ ID NO: 103) and DDDDE (SEQ ID NO: 94).

These PR39-derivatives were made by PCR in a standard PCR reaction using a
25 specific forward primer in connection with a general reverse primer pBAD-Rev, both of which are set out below. The PCR template was a pHH plasmid encoding the wildtype PR39 (wt PR39), SEQ ID NO: 65.

The PCR fragments were purified, restricted with NcoI and XbaI and cloned into the corresponding sites in pHH. The sequence of these constructs was verified by DNA
30 sequencing using the primers pBAD-forw and pBAD-rev, see below.

The results from the testing in the SES system were that each of the five derivatives of PR39 resulted in a decreased inhibition as compared to the inhibition of wt PR-39. A decrease in inhibition is indicative of a decrease in antimicrobial activity and hence indicative of efficient quenching. Also, a gradually decreasing inhibition was observed along the following series of
35 N-terminal extensions: E, DE, DDE, DDDE (SEQ ID NO: 103) and DDDDE (SEQ ID NO: 94). In other words, the largest inhibition was observed with E, followed by DE, then by DDE, then by DDDE (SEQ ID NO: 103), whereas DDDDE (SEQ ID NO: 94) exhibited the minimum

inhibition observed in this experiment.

These are the primers that were used to amplify and sequence the five PR-39 derivatives:

5 pHH1531 (E-PR39)

Primer pHH1531-Forw:

catagcaccatggaaggagacgtccccgacccccatattgcc (SEQ ID NO: 66)

pHH1532 (DE-PR39)

10 Primer pHH1532-Forw:

catagcaccatggatgaaaggagacgtccccgacccccatattgcc (SEQ ID NO: 67)

pHH1533 (DDE-PR39)

Primer pHH1533-Forw:

15 catagcaccatggacgatgaaaggagacgtccccgacccccatattgcc (SEQ ID NO: 68)

pHH1534 (DDDE-PR39)

Primer pHH1534-Forw:

catagcaccatggatgacgatgaaaggagacgtccccgacccccatattgcc (SEQ ID NO: 69)

20

pHH1535 (DDDDE-PR39)

Primer pHH1535-Forw:

catagcaccatggacgatgacgatgaaaggagacgtccccgacccccatattgcc (SEQ ID NO: 70)

25 pBAD-forw:

CCATAAGATTAGCGGATCCTACC (SEQ ID NO: 71)

pBAD-rev:

CTCTCATCCGCCAAAACAGCC (SEQ ID NO: 72)

30

Example 4: Use of quenching domains in the expression and secretion of antimicrobial agents in yeast

This example illustrates the expression and secretion of two different antimicrobial peptides, Novispirin and PR39, in the yeast *Saccharomyces cerevisiae* using specific quenching domains.

35

Novispirin G10 is an antimicrobial peptide composed of the following amino acids: KNLRRIRKGIHIKKYG (SEQ ID NO: 73).

First five different PR39 fusion constructs were made, viz. E-PR39, DE-PR39, DDE-PR39, DDDE(SEQ ID NO: 103)-PR39 and DDDDE(SEQ ID NO: 94)-PR39.

As some proteases specifically cleave after glutamic acid residues (E), the added quenching domain can be liberated from the AMP allowing for monitoring of the antimicrobial activity of the AMP.

The PR39-derivatives were amplified using specific Forward primers and a general reverse primer pBAD-rev that are indicated below in a standard PCR reaction. The PCR templates used were those generated in Example 3.

Derivative	PCR Template	Fwdprimer	Revprimer
pHH3857 (E-PR39)	pHH1531	pHH3857 fwd	pBAD rev
pHH3858 (DE-PR39)	pHH1532	pHH3858 fwd	pBAD rev
pHH3859 (DDE-PR39)	pHH1533	pHH3859 fwd	pBAD rev
pHH3860 (DDDE-PR39)	pHH1534	pHH3860 fwd	pBAD rev
pHH3861 (DDDDE-PR39)	pHH1535	pHH3861 fwd	pBAD rev

10

Primer sequences

pHH3857 fwd:

AGGGGTATCGATGGCTAAGAGAGAAGCCGAAAGGAGACGTCCCCGACCCCC (SEQ ID NO: 74)

15

pHH3858 fwd:

AGGGGTATCGATGGCTAAGAGAGAAGCCGATGAAAGGAGACGTCCCCGACCCCC (SEQ ID NO: 75)

20

pHH3859 fwd:

AGGGGTATCGATGGCTAAGAGAGAAGCCGACGATGAAAGGAGACGTCCCCGACCCCC (SEQ ID NO: 76)

pHH3860 fwd:

25 AGGGGTATCGATGGCTAAGAGAGAAGCCGATGACGATGAAAGGAGACGTCCCCGACCCC (SEQ ID NO: 77)

pHH3861 fwd:

30 AGGGGTATCGATGGCTAAGAGAGAAGCCGACGATGACGATGAAAGGAGACGTCCCCGACCCCC (SEQ ID NO: 78)

The resulting five PCR fragments were purified, restricted with Clal and XbaI and cloned into a suitable yeast expression vector such as the commercially available vector pYES2. The five derivatives were verified by DNA sequencing, and transformed into a suitable strain of *S. cerevisiae* using a PEG/LiAc protocol.

5 Distinct bands with the expected molecular weight were observed in each of the five cultures indicating expression of the peptides. Again it appeared that the longer the quenching domains, the larger the amounts produced of the antimicrobial peptide, the effectiveness increasing in the order E < DE < DDE < DDDE < DDDDE. No bands were observed in supernatants of yeast cells harboring the control plasmid (without antimicrobial peptide).

10 The samples that encoded PR-39 showed distinct bands of the anticipated sizes on Tricine SDS-PAGE gels (Schagger & Von Jagow (87) Anal. Bioch. 166, 368 - 379).

 Prior to digestion with the C-component protease no antimicrobial activity was detected in any supernatants that was analysed for antimicrobial activity as described in example 1. But after separation of the quenching domains from the antimicrobial peptide, clearing zones were
15 observed in the samples encoding PR39. No clearing zone was detected in control samples.

 In the same manner as described above, further constructs were made in yeast and found to allow for satisfactory expression and secretion of the antimicrobial peptide. The further constructs were the following:

- pHH3864: E-Novispirin (SEQ ID NO: 73)
20 pHH3865: DDE-Novispirin (SEQ ID NO: 73)
pHH3866: DDDDE(SEQ ID NO: 94)-Novispirin (SEQ ID NO: 73)
pHH3879: DEDEDEDP(SEQ ID NO: 104)-Novispirin (SEQ ID NO: 73)
pHH3880: DEDEDEDP(SEQ ID NO: 104)-PR-39 (SEQ ID NO: 65)
pHH3883: DDDGGEEEGDDDDP(SEQ ID NO: 105)-PR-39 (SEQ ID NO: 65)
25 pHH3884: DDDGGDDDDPPDDDE(SEQ ID NO: 106)-PR-39 (SEQ ID NO: 65).

Example 5: Exploiting the distance between the quenching domain and the antimicrobial agent

 To investigate the effect of the translational distance between the antimicrobial peptide
30 and the quenching domain two new constructs were created. An expression setup similar to the one described in Example 4 was employed, i.e. a pYES2-derived vector utilizing the alpha-leader to allow secretion of the produced peptides.

 In one construct, pHH3891, an eight amino acid glycine linker was inserted between PR-39 (SEQ ID NO: 65) and the quenching domain DDDDE (SEQ ID NO: 94). In the other
35 construct, pHH3892, a twelve amino acid glycine linker was used. The plasmids were constructed by standard molecular biology methods, verified by DNA sequencing and transformed into yeast as described in Example 4.

pHH3891 (SEQ ID NO: 117):

DDDDE-GGGGGGGGE-RRRPRPPYLPRRPPPPFFPRLPPRIPPGFPPRFPPRFP

pHH3892 (SEQ ID NO: 118):

DDDDE-GGGGGGGGGGGGE-RRRPRPPYLPRRPPPPFFPRLPPRIPPGFPPRFPPRFP

5 Two independent transformants of each of the two constructs were grown in the yeast minimal medium SC (see p. 174 in *Methods in Yeast Genetics 2000* A Cold Spring Harbor Laboratory Course Manual by Dan Burke, ISBN 0-87969-588-9 / 0879695889) supplemented with 2% glucose and incubated under shaking at 35°C for 3 days. The supernatants were harvested and analyzed on Bis-Tris gels as recommended by the manufacturer (Invitrogen,
10 Carlsbad, CA, USA).

All four supernatants contained a peptide with the apparent and expected size of 6 kDa. The peptides produced in pHH3891 and pHH3892 have a theoretical molecular weight (MW) of 6006 Da and 6234 Da, respectively.

15 The results indicate flexibility as regards the translational distance between the AMP and the quenching domain (protection peptide).

Example 6: Co-expression of an enzyme and an antimicrobial agent

This example illustrates co-expression in, and secretion from, recombinant bacteria of a pectate lyase enzyme and either of two antimicrobial peptides, as fusion proteins.

20 The gene encoding a pectate lyase derived from *Bacillus licheniformis* (amino acids 28-341 of SEQ ID NO: 2 of WO 00/75344) and a) an Anti Fungal Peptide (AFP) from *Aspergillus giganteus* (SEQ ID NO: 2 of WO 94/01459), or b) the antimicrobial peptide designated G10 novispirin (an artificial peptide having SEQ ID NO: 17 of US patent no. 6,492,328), was made and inserted along with the chloramphenicol resistance gene *cat* into
25 the *amyE* locus on the chromosome of *Bacillus subtilis*. The *B. subtilis* host strain used was the protease deficient strain designated WB600asn (a chloramphenicol sensitive derivative of *B. subtilis* strain WB600 which is described in *J. Bact.* 1991. p. 4952-4958). Both of the fusion proteins according to a) and b) above were secreted into the culture broth.

30 The expression cassette was an *amyQ* promoter from *Bacillus amyloliquefaciens* in front of the *cryIIIA* promoter plus the mRNA stabilization element from *Bacillus thuringiensis*. (see US patent no 6,255,076, in particular the pDG268 neo system shown in Fig. 19 thereof).

The following DNA fragments were prepared:

(A) The Shine Delgarno sequence (SD) and the signal peptide were derived from the *amyL* gene of *Bacillus licheniformis* (ATCC 14580), viz. as the PCR fragment amplified by
35 below primers 1 and 2 with *Sac1* and *Pst1* tails:

Primer 1: tatagagctCCATTGAAAGGGGAGGAGAATC-3' (SEQ ID NO: 107)

Primer 2: tataCTGCAGAATGAGGCAGCAAGAAGATGAGC-3' (SEQ ID NO: 108);

(B) The coding region of the pectate lyase gene was also derived from *Bacillus licheniformis* (ATCC 14580), viz. as the PCR fragment amplified by below primers 3 and 4 with Pst1 and Nhe1 tails:

Primer 3: tataCTGCAGCCGCGGCAGCTTCTGCCTTAAAC-3' (SEQ ID NO: 109)

5 Primer 4: tataGCTAGCTGGATTGATTTTGCCGACTCCG-3' (SEQ ID NO: 110);

(C1) A synthetic gene containing the coding region for the AFP sequence (nucleotides 1066-1218 of SEQ ID NO: 111) with Nhe1 and Mlu1 tails.

Primer 5: tataacgctTCTAGCAGTGGCACTTG-3' (SEQ ID NO: 113)

10 (C2) A synthetic gene containing the coding region for the G10 novispirin sequence (nucleotides 1236-1289 of SEQ ID NO: 114) with Nhe1 and Mlu1 tails.

Primer 6: tataacgctTTATCCGTATTTCTTAATG-3' (SEQ ID NO: 116)

The three fragments ((A) + (B) + (C1)), or ((A) + (B) + (C2)) were assembled after Restriction Enzyme digestion (Pst1 + Nhe1), DNA ligation and PCR amplification (PP1223-9 PCR primer 1 + primer 5, DNA template: Ligation of fragment (A) + (B) + (C1)), (PP1331-2
15 PCR primer 1 + primer 6, DNA template: ligation of fragment (A) + (B) + (C2)), and finally inserted into the vector part of the pDG268neo plasmid as a Sac1 Mlu1 fragment (the unique Mlu1 site is situated in the C-terminal part of the Savinase gene in pDG268neo plasmid).

The plasmid with the above expression cassette and the cat gene flanked by amyE sequences was then transferred to competent cells of *Bacillus subtilis* WB600. Among the
20 chloramphenicol resistant transformants a colony with the correct expression cassette inserted into the amyE gene was isolated, and the gene sequence of the inserted pectate lyase fusion peptide confirmed by DNA sequencing.

In the PP1223-9 *Bacillus subtilis* strain the pectate lyase gene is fused in frame to the DNA sequence encoding the AFP from *Aspergillus giganteus*. The fusion protein secreted
25 from PP1223-9 (amino acids 1-368 of SEQ ID NO: 112) was identified as a major band of the correct size (40 kDal) by running the culture broth on an SDS PAGE gel:

MKQQKRLYARLLTLLFALIFLLPHSAAAAASALNSGKVNPLADFSLKGFAALNGGTTGG
EGGQTVTVTTGDQLIAALKNKNANTPLKIYVNGTITTSNTSASKIDVKDVSNSIVGSGTKGELK
GIGIKIWRANNIIIRNLKIHEVASGDKDAIGIEGPSKNIWVDHNELYHSLNVDKDYDGLDFVVKRD
30 *AEYITFSWNYVHDGWKSMMLMGSSDSNYNRTITFHNNWFENLSRVPSFRFGEGHIYNNYF*
NKIIDSGINSRMGARIRIENLNFENAKDPIVSWYSSSPGYWHVSNNKFVNSRGSMPPTSTTTY
NPPYSYSLDNVDNVKSIVKQNAVGVGKINPASEATYPGKCYKKNICKYKAQSGKTGICKCYVK
RCPRDGAKCDLDSYKKGKCHC (SEQ ID NO: 112). The DNA fragment corresponding to SEQ
ID NO: 112 is the PP1223-9 Sac1 Mlu1 DNA fragment of SEQ ID NO: 111.

35 The N-terminal signal peptide part of SEQ ID NO: 112 (underlined) is cleaved off before secretion of the mature fusion peptide. The underlined C-terminal tail region is the AFP. The mature pectate lyase part is shown in italics.

In the PP1331-2 *Bacillus subtilis* strain the pectate lyase gene is fused in frame to the DNA sequence encoding a larger linker (a stretch of negatively charged amino acids) and G10 novispirin. The fusion protein secreted from PP1331-2 (amino acids 1-392 of SEQ ID NO: 115) was identified as a major band of the correct size (43 kDal) by running the culture broth on an SDS PAGE gel:

5 MKQQKRLYARLLTLLFALIFLLPHSAAAAASALNSGKVNPLADFSLKGFAALNGGTTGG
 EGGQTVTVTTGDQLIAALKKNANTPLKIYVNGTITTSNTSASKIDVKDVSNSVIVGSGTKGELK
 GIGIKIWRANNIIIIRNLKIHEVASGDKDAIGIEGPSKNIWVDHNELYHSLNVDKDYDGLFDVKRD
 AEYITFSWNYVHDGWKSMLMGSSDSNYNRTITFHHNWFENLNSRVSSFRFGEGHIYNNYF
 10 *NKIIDSGINSRMGARIRIENLNFENAKDPIVSWYSSSPGYWHVSNNKFVNSRGSMPPTSTTTY*
 NPPYSYSLDNVDNVKSIVKQAGVGKINPASLDKREAEACEEERNAEEERRDEPDERDAQVE
 HNAREAEADAEAVGPEAFADLDPWEKNLRRRIIRKGIHIIKKYG (SEQ ID NO: 115).

15 The N-terminal signal peptide part (underlined) of SEQ ID NO: 115 is cleaved off before secretion of the mature fusion peptide. The underlined C-terminal tail region is the G10 novispirin. The mature pectate lyase part is shown in italics. The DNA fragment corresponding to SEQ ID NO: 115 is the PP1331-2 Sac1 Mlu1 DNA fragment of SEQ ID NO: 114.

Claims

1. A recombinant microbial host cell comprising a first nucleic acid sequence encoding an antimicrobial agent, and a second heterologous nucleic acid sequence encoding an enzyme.
- 5
2. The host cell of claim 1, wherein the first and/or the second nucleic acid sequence(s) is/are integrated into the chromosome of the host cell.
3. The host cell of claim 1, which contains a DNA construct incorporating the first as well
- 10 as the second nucleic acid sequence.
4. The host cell of claim 1, wherein the first nucleic acid sequence is incorporated in a first DNA construct and the second nucleic acid sequence is incorporated in a second DNA construct.
- 15
5. The host cell of claim 4, further comprising a third DNA construct incorporating the first as well as the second nucleic acid sequence.
6. A nucleic acid construct comprising a first nucleic acid sequence encoding an antimicrobial agent, and a second nucleic acid sequence encoding an enzyme, operably linked
- 20 to one or more control sequences that direct the expression of the enzyme and the antimicrobial agent in a suitable expression host, wherein the second nucleic acid sequence is heterologous to the expression host.
7. A method for producing an enzyme and/or an antimicrobial agent, the method comprising: (a) cultivating the recombinant host cell of any one of claims 1-5 to produce a supernatant comprising the enzyme and the antimicrobial agent; and (b) recovering the enzyme and/or the antimicrobial agent.
- 25
8. A fusion product comprising an enzyme, an antimicrobial agent, and a cleavable linker.
- 30
9. An animal feed additive comprising
- (a) at least one fusion product of claim 8,
- (b) at least one fat-soluble vitamin, and/or
- (c) at least one water-soluble vitamin, and/or
- 35 (d) at least one trace mineral.

10. An animal feed composition having a crude protein content of 50 to 800 g/kg and comprising at least one fusion product of claim 8.
11. A transgenic, non-human animal, or products, or elements thereof, capable of
5 expressing an enzyme and an antimicrobial agent.
12. Use of the fusion product of claim 8 in animal feed.
13. Use of co-expression of an antimicrobial agent and an enzyme as a tool to improve the
10 yield of the antimicrobial agent and/or to improve overall production economy.
14. In the recombinant expression of an antimicrobial peptide, the use of a protection
peptide, wherein at least 50% of the amino acid residues comprised in the protection peptide
are D (Asp) and/or E (Glu).
15
15. A method for identifying a protection peptide comprising at least one D (Asp) and/or E
(Glu), the method comprising:
- a) providing a peptide protection candidate comprising at least one D and/or E;
 - b) preparing a DNA construct comprising a first DNA sequence encoding the peptide
20 protection candidate and a second DNA sequence encoding an antimicrobial peptide;
 - c) transforming a host cell with the DNA construct of b) and cultivating the transformed
host cell to obtain expression of the DNA construct;
 - d) estimating viability of the transformed host cell and/or yield of antimicrobial peptide;
and
 - 25 e) identifying a peptide protection candidate which when used in a DNA construct
according to step b), for transformation of a host cell according to step c), results in an
increased viability of the host cell, and/or an increased yield of antimicrobial peptide, when
estimated according to step d).
- 30 16. Use of a protection peptide identified by the method of claim 15 in the recombinant
expression of an antimicrobial peptide.
17. The host cell of any one of claims 1 to 5, further comprising a DNA sequence encoding
a protection peptide.
35
18. The nucleic acid construct of claim 6, further comprising a DNA sequence encoding a
protection peptide.

19. The method of claim 7, wherein the recombinant host cell is according to claim 17.

20. The fusion product of claim 8, further comprising a protection peptide.

5

21. The use of claim 13, further comprising the use of a protection peptide.

10486.204-WO.ST25
SEQUENCE LISTING

<110> Novozymes A/S
 <120> Recombinant Production of Antimicrobial Agents
 <130> 10486
 <160> 118
 <170> PatentIn version 3.2
 <210> 1
 <211> 20
 <212> PRT
 <213> Artificial
 <220>
 <223> Peptide
 <220>
 <221> PEPTIDE
 <222> (1)..(20)
 <220>
 <221> DISULFID
 <222> (2)..(19)
 <400> 1
 Lys Cys Arg Arg Trp Gln Trp Arg Met Lys Lys Leu Gly Ala Pro Ser
 1 5 10 15
 Ile Thr Cys Val
 20
 <210> 2
 <211> 20
 <212> PRT
 <213> Artificial
 <220>
 <223> Peptide
 <220>
 <221> MISC_FEATURE
 <223> The thiol group of the Cys in position 2 is blocked
 <220>
 <221> MISC_FEATURE
 <223> The thiol group of the Cys in position 19 is blocked
 <220>
 <221> PEPTIDE
 <222> (1)..(20)
 <400> 2
 Lys Cys Arg Arg Trp Gln Trp Arg Met Lys Lys Leu Gly Ala Pro Ser
 1 5 10 15
 Ile Thr Cys Val
 20

10486.204-WO.ST25

<210> 3
 <211> 20
 <212> PRT
 <213> Artificial

<220>
 <223> Peptide

<220>
 <221> PEPTIDE
 <222> (1)..(20)

<220>
 <221> DISULFID
 <222> (2)..(19)

<400> 3

Lys Cys Phe Gln Trp Gln Arg Asn Met Arg Lys Val Arg Gly Pro Pro
 1 5 10 15

Val Ser Cys Ile
 20

<210> 4
 <211> 20
 <212> PRT
 <213> Artificial

<220>
 <223> Peptide

<220>
 <221> MISC_FEATURE
 <223> The thiol group of Cys in position 2 is blocked

<220>
 <221> MISC_FEATURE
 <223> The thiol group of Cys in position 19 is blocked

<220>
 <221> PEPTIDE
 <222> (1)..(20)

<400> 4

Lys Cys Phe Gln Trp Gln Arg Asn Met Arg Lys Val Arg Gly Pro Pro
 1 5 10 15

Val Ser Cys Ile
 20

<210> 5
 <211> 5
 <212> PRT
 <213> Artificial

<220>
 <223> Peptide

10486.204-WO.ST25

<220>
<221> PEPTIDE
<222> (1)..(5)

<400> 5

Arg Trp Gln Trp Arg
1 5

<210> 6
<211> 5
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> PEPTIDE
<222> (1)..(5)

<400> 6

Arg Arg Gln Trp Arg
1 5

<210> 7
<211> 5
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> PEPTIDE
<222> (1)..(5)

<400> 7

Lys Val Ser Trp Arg
1 5

<210> 8
<211> 5
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> PEPTIDE
<222> (1)..(5)

<400> 8

Arg Asn Met Arg Lys
1 5

10486.204-WO.ST25

<210> 9
<211> 5
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> PEPTIDE
<222> (1)..(5)

<400> 9

Arg Trp Gln Glu Lys
1 5

<210> 10
<211> 6
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> PEPTIDE
<222> (1)..(6)

<400> 10

Arg Arg Trp Gln Trp Arg
1 5

<210> 11
<211> 6
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> PEPTIDE
<222> (1)..(6)

<400> 11

Arg Arg Arg Gln Trp Arg
1 5

<210> 12
<211> 6
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> PEPTIDE

10486.204-WO.ST25

<222> (1)..(6)

<400> 12

Lys Thr Val Ser Trp Arg
1 5

<210> 13

<211> 6

<212> PRT

<213> Artificial

<220>

<223> Peptide

<220>

<221> PEPTIDE

<222> (1)..(6)

<400> 13

Lys Arg Asn Met Arg Lys
1 5

<210> 14

<211> 6

<212> PRT

<213> Artificial

<220>

<223> Peptide

<220>

<221> PEPTIDE

<222> (1)..(6)

<400> 14

Arg Trp Gln Glu Met Lys
1 5

<210> 15

<211> 11

<212> PRT

<213> Artificial

<220>

<223> Peptide

<220>

<221> PEPTIDE

<222> (1)..(11)

<400> 15

Lys Thr Arg Arg Trp Gln Trp Arg Met Lys Lys
1 5 10

<210> 16

<211> 11

<212> PRT

10486.204-WO.ST25

<213> Artificial

<220>

<223> Peptide

<220>

<221> PEPTIDE

<222> (1)..(11)

<400> 16

Lys Ser Arg Arg Arg Gln Trp Arg Met Lys Lys
1 5 10

<210> 17

<211> 11

<212> PRT

<213> Artificial

<220>

<223> Peptide

<220>

<221> PEPTIDE

<222> (1)..(11)

<400> 17

Lys Thr Val Ser Trp Gln Thr Tyr Met Lys Lys
1 5 10

<210> 18

<211> 11

<212> PRT

<213> Artificial

<220>

<223> Peptide

<220>

<221> PEPTIDE

<222> (1)..(11)

<400> 18

Lys Thr Phe Gln Trp Gln Arg Asn Met Arg Lys
1 5 10

<210> 19

<211> 11

<212> PRT

<213> Synthetic

<220>

<221> PEPTIDE

<222> (1)..(11)

<400> 19

Lys Thr Leu Arg Trp Gln Asn Glu Met Arg Lys
1 5 10

10486.204-WO.ST25

<210> 20
<211> 6
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> PEPTIDE
<222> (1)..(6)

<400> 20

Phe Gln Trp Gln Arg Asn
1 5

<210> 21
<211> 5
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> PEPTIDE
<222> (1)..(5)

<400> 21

Phe Gln Trp Gln Arg
1 5

<210> 22
<211> 4
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> PEPTIDE
<222> (1)..(4)

<400> 22

Gln Trp Gln Arg
1

<210> 23
<211> 3
<212> PRT
<213> Artificial

<220>
<223> Peptide

10486.204-WO.ST25

<220>
<221> PEPTIDE
<222> (1)..(3)

<400> 23

Trp Gln Arg
1

<210> 24
<211> 5
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> PEPTIDE
<222> (1)..(5)

<400> 24

Arg Arg Trp Gln Trp
1 5

<210> 25
<211> 4
<212> PRT
<213> Synthetic

<220>
<221> PEPTIDE
<222> (1)..(4)

<400> 25

Arg Arg Trp Gln
1

<210> 26
<211> 4
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> PEPTIDE
<222> (1)..(4)

<400> 26

Trp Gln Trp Arg
1

<210> 27
<211> 3
<212> PRT
<213> Artificial

10486.204-WO.ST25

<220>
<223> Peptide

<220>
<221> PEPTIDE
<222> (1)..(3)

<400> 27

Gln Trp Arg
1

<210> 28
<211> 6
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> PEPTIDE
<222> (1)..(3)

<400> 28

Leu Arg Trp Gln Asn Asp
1 5

<210> 29
<211> 5
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> PEPTIDE
<222> (1)..(5)

<400> 29

Leu Arg Trp Gln Asn
1 5

<210> 30
<211> 4
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> PEPTIDE
<222> (1)..(4)

<400> 30

10486.204-WO.ST25

Leu Arg Trp Gln
1

<210> 31
<211> 3
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> PEPTIDE
<222> (1)..(3)

<400> 31

Arg Trp Gln
1

<210> 32
<211> 25
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> PEPTIDE
<222> (1)..(25)

<400> 32

Phe Lys Cys Arg Arg Trp Gln Trp Arg Met Lys Lys Leu Gly Ala Pro
1 5 10 15

Ser Ile Thr Cys Val Arg Arg Ala Phe
20 25

<210> 33
<211> 11
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> PEPTIDE
<222> (1)..(11)

<220>
<221> misc_feature
<222> (2)..(5)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (7)..(8)
<223> Xaa can be any naturally occurring amino acid

10486.204-wo.ST25

<400> 33

Lys Xaa Xaa Xaa Xaa Gln Xaa Xaa Met Lys Lys
 1 5 10

<210> 34
 <211> 11
 <212> PRT
 <213> Artificial

<220>
 <223> Peptide

<220>
 <221> PEPTIDE
 <222> (1)..(11)

<220>
 <221> misc_feature
 <222> (2)..(5)
 <223> Xaa can be any naturally occurring amino acid

<220>
 <221> misc_feature
 <222> (7)..(8)
 <223> Xaa can be any naturally occurring amino acid

<400> 34

Lys Xaa Xaa Xaa Xaa Gln Xaa Xaa Met Arg Lys
 1 5 10

<210> 35
 <211> 6
 <212> PRT
 <213> Artificial

<220>
 <223> Peptide

<220>
 <221> PEPTIDE
 <222> (1)..(6)

<220>
 <221> misc_feature
 <222> (2)..(5)
 <223> Xaa can be any naturally occurring amino acid

<400> 35

Arg Xaa Xaa Xaa Xaa Arg
 1 5

<210> 36
 <211> 6
 <212> PRT
 <213> Artificial

<220>
 <223> Peptide

10486.204-WO.ST25

<220>
<221> PEPTIDE
<222> (1)..(6)

<220>
<221> misc_feature
<222> (2)..(5)
<223> Xaa can be any naturally occurring amino acid

<400> 36

Lys Xaa Xaa Xaa Xaa Arg
1 5

<210> 37
<211> 6
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> PEPTIDE
<222> (1)..(6)

<220>
<221> misc_feature
<222> (2)..(5)
<223> Xaa can be any naturally occurring amino acid

<400> 37

Lys Xaa Xaa Xaa Xaa Lys
1 5

<210> 38
<211> 6
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> PEPTIDE
<222> (1)..(6)

<220>
<221> misc_feature
<222> (2)..(5)
<223> Xaa can be any naturally occurring amino acid

<400> 38

Arg Xaa Xaa Xaa Xaa Lys
1 5

<210> 39
<211> 5
<212> PRT
<213> Artificial

10486.204-WO.ST25

<220>

<223> Peptide

<220>

<221> PEPTIDE

<222> (1)..(5)

<220>

<221> misc_feature

<222> (2)..(4)

<223> Xaa can be any naturally occurring amino acid

<400> 39

Arg Xaa Xaa Xaa Arg
1 5

<210> 40

<211> 5

<212> PRT

<213> Synthetic

<220>

<221> PEPTIDE

<222> (1)..(5)

<220>

<221> misc_feature

<222> (2)..(4)

<223> Xaa can be any naturally occurring amino acid

<400> 40

Lys Xaa Xaa Xaa Arg
1 5

<210> 41

<211> 5

<212> PRT

<213> Synthetic

<220>

<221> PEPTIDE

<222> (1)..(5)

<220>

<221> misc_feature

<222> (2)..(4)

<223> Xaa can be any naturally occurring amino acid

<400> 41

Arg Xaa Xaa Xaa Lys
1 5

<210> 42

<211> 38

<212> PRT

<213> Artificial

<220>

10486.204-wo.ST25

<223> Peptide

<220>

<221> PEPTIDE

<222> (1)..(38)

<400> 42

Lys Asn Val Arg Trp Cys Thr Ile Ser Gln Pro Glu Trp Phe Lys Cys
 1 5 10 15

Arg Arg Trp Gln Trp Arg Met Lys Lys Leu Gly Ala Pro Ser Ile Thr
 20 25 30

Cys Val Arg Arg Ala Phe
 35

<210> 43

<211> 32

<212> PRT

<213> Artificial

<220>

<223> Peptide

<220>

<221> PEPTIDE

<222> (1)..(32)

<400> 43

Thr Ile Ser Gln Pro Glu Trp Phe Lys Cys Arg Arg Trp Gln Trp Arg
 1 5 10 15

Met Lys Lys Leu Gly Ala Pro Ser Ile Thr Cys Val Arg Arg Ala Phe
 20 25 30

<210> 44

<211> 36

<212> PRT

<213> Artificial

<220>

<223> Peptide

<220>

<221> PEPTIDE

<222> (1)..(36)

<400> 44

Val Ser Gln Pro Glu Ala Thr Lys Cys Phe Gln Trp Gln Arg Asn Met
 1 5 10 15

Arg Lys Val Arg Gly Pro Pro Val Ser Cys Ile Lys Arg Asp Ser Pro
 20 25 30

Ile Gln Cys Ile

10486.204-WO.ST25

35

<210> 45
 <211> 5
 <212> PRT
 <213> Artificial

<220>
 <223> Peptide

<220>
 <221> PEPTIDE
 <222> (1)..(5)

<220>
 <221> misc_feature
 <222> (2)..(4)
 <223> Xaa can be any naturally occurring amino acid

<400> 45

Lys Xaa Xaa Xaa Lys
 1 5

<210> 46
 <211> 11
 <212> PRT
 <213> Artificial

<220>
 <223> Peptide

<220>
 <221> PEPTIDE
 <222> (1)..(11)

<400> 46

Gly Arg Arg Arg Arg Ser Val Gln Trp Cys Ala
 1 5 10

<210> 47
 <211> 50
 <212> PRT
 <213> Artificial

<220>
 <223> Peptide

<220>
 <221> PEPTIDE
 <222> (1)..(50)

<400> 47

Ala Pro Arg Lys Asn Val Arg Trp Cys Thr Ile Ser Gln Pro Glu Trp
 1 5 10 15

Phe Lys Cys Arg Arg Trp Gln Trp Arg Met Lys Lys Leu Gly Ala Pro
 20 25 30

10486.204-WO.ST25

Ser Ile Thr Cys Val Arg Arg Ala Phe Ala Leu Glu Cys Ile Arg Ala
 35 40 45

Ile Ala
 50

<210> 48
 <211> 18
 <212> PRT
 <213> Artificial

<220>
 <223> Peptide

<220>
 <221> PEPTIDE
 <222> (1)..(18)

<400> 48

Pro Glu Trp Phe Lys Cys Arg Arg Trp Gln Trp Arg Met Lys Lys Leu
 1 5 10 15

Gly Ala

<210> 49
 <211> 15
 <212> PRT
 <213> Artificial

<220>
 <223> Peptide

<220>
 <221> PEPTIDE
 <222> (1)..(15)

<400> 49

Phe Lys Cys Arg Arg Trp Gln Trp Arg Met Lys Lys Leu Gly Ala
 1 5 10 15

<210> 50
 <211> 14
 <212> PRT
 <213> Artificial

<220>
 <223> Peptide

<220>
 <221> PEPTIDE
 <222> (1)..(14)

<400> 50

Lys Cys Arg Arg Trp Gln Trp Arg Met Lys Lys Leu Gly Ala
 1 5 10

10486.204-WO.ST25

<210> 51
 <211> 13
 <212> PRT
 <213> Artificial

<220>
 <223> Peptide

<220>
 <221> PEPTIDE
 <222> (1)..(13)

<400> 51

Cys Arg Arg Trp Gln Trp Arg Met Lys Lys Leu Gly Ala
 1 5 10

<210> 52
 <211> 12
 <212> PRT
 <213> Artificial

<220>
 <223> Peptide

<220>
 <221> PEPTIDE
 <222> (1)..(12)

<400> 52

Arg Arg Trp Gln Trp Arg Met Lys Lys Leu Gly Ala
 1 5 10

<210> 53
 <211> 15
 <212> PRT
 <213> Artificial

<220>
 <223> Peptide

<220>
 <221> PEPTIDE
 <222> (1)..(15)

<400> 53

Lys Lys Cys Arg Arg Trp Gln Trp Arg Met Lys Lys Leu Gly Ala
 1 5 10 15

<210> 54
 <211> 15
 <212> PRT
 <213> Artificial

<220>
 <223> Peptide

10486.204-WO.ST25

<220>

<221> PEPTIDE

<222> (1)..(15)

<400> 54

Phe Lys Cys Phe Arg Trp Gln Trp Arg Met Lys Lys Leu Gly Ala
 1 5 10 15

<210> 55

<211> 15

<212> PRT

<213> Artificial

<220>

<223> Peptide

<220>

<221> PEPTIDE

<222> (1)..(15)

<400> 55

Lys Lys Cys Phe Arg Trp Gln Trp Arg Met Lys Lys Leu Gly Ala
 1 5 10 15

<210> 56

<211> 14

<212> PRT

<213> Artificial

<220>

<223> Peptide

<220>

<221> PEPTIDE

<222> (1)..(14)

<400> 56

Phe Lys Cys Arg Arg Trp Gln Trp Arg Met Lys Lys Leu Gly
 1 5 10

<210> 57

<211> 19

<212> PRT

<213> Artificial

<220>

<223> Peptide

<220>

<221> PEPTIDE

<222> (1)..(19)

<400> 57

Cys Arg Arg Trp Gln Trp Arg Met Lys Lys Leu Gly Ala Pro Ser Ile
 1 5 10 15

Thr Cys Val

10486.204-WO.ST25

<210> 58
 <211> 6
 <212> PRT
 <213> Artificial

<220>
 <223> Peptide

<220>
 <221> PEPTIDE
 <222> (1)..(6)

<400> 58

Arg Arg Trp Gln Trp Arg
 1 5

<210> 59
 <211> 188
 <212> PRT
 <213> Nocardiosis sp.

<220>
 <221> mat_peptide
 <222> (1)..(188)

<400> 59

Ala Asp Ile Ile Gly Gly Leu Ala Tyr Thr Met Gly Gly Arg Cys Ser
 1 5 10 15

Val Gly Phe Ala Ala Thr Asn Ala Ala Gly Gln Pro Gly Phe Val Thr
 20 25 30

Ala Gly His Cys Gly Arg Val Gly Thr Gln Val Thr Ile Gly Asn Gly
 35 40 45

Arg Gly Val Phe Glu Gln Ser Val Phe Pro Gly Asn Asp Ala Ala Phe
 50 55 60

Val Arg Gly Thr Ser Asn Phe Thr Leu Thr Asn Leu Val Ser Arg Tyr
 65 70 75 80

Asn Thr Gly Gly Tyr Ala Ala Val Ala Gly His Asn Gln Ala Pro Ile
 85 90 95

Gly Ser Ser Val Cys Arg Ser Gly Ser Thr Thr Gly Trp His Cys Gly
 100 105 110

Thr Ile Gln Ala Arg Gly Gln Ser Val Ser Tyr Pro Glu Gly Thr Val
 115 120 125

Thr Asn Met Thr Arg Thr Thr Val Cys Ala Glu Pro Gly Asp Ser Gly
 130 135 140

10486.204-WO.ST25

Gly Ser Tyr Ile Ser Gly Thr Gln Ala Gln Gly Val Thr Ser Gly Gly
 145 150 155 160

Ser Gly Asn Cys Arg Thr Gly Gly Thr Thr Phe Tyr Gln Glu Val Thr
 165 170 175

Pro Met Val Asn Ser Trp Gly Val Arg Leu Arg Thr
 180 185

<210> 60
 <211> 354
 <212> PRT
 <213> Nocardiosis dassonvillei subsp. dassonvillei

<220>
 <221> mat_peptide
 <222> (167)..(354)

<400> 60

Ala Pro Ala Pro Val Pro Gln Thr Pro Val Ala Asp Asp Ser Ala
 -165 -160 -155

Ala Ser Met Thr Glu Ala Leu Lys Arg Asp Leu Asp Leu Thr Ser
 -150 -145 -140

Ala Glu Ala Glu Glu Leu Leu Ser Ala Gln Glu Ala Ala Ile Glu
 -135 -130 -125

Thr Asp Ala Glu Ala Thr Glu Ala Ala Gly Glu Ala Tyr Gly Gly
 -120 -115 -110

Ser Leu Phe Asp Thr Glu Thr Leu Glu Leu Thr Val Leu Val Thr Asp
 -105 -100 -95

Ala Ser Ala Val Glu Ala Val Glu Ala Thr Gly Ala Gln Ala Thr Val
 -90 -85 -80 -75

Val Ser His Gly Thr Glu Gly Leu Thr Glu Val Val Glu Asp Leu Asn
 -70 -65 -60

Gly Ala Glu Val Pro Glu Ser Val Leu Gly Trp Tyr Pro Asp Val Glu
 -55 -50 -45

Ser Asp Thr Val Val Val Glu Val Leu Glu Gly Ser Asp Ala Asp Val
 -40 -35 -30

Ala Ala Leu Leu Ala Asp Ala Gly Val Asp Ser Ser Ser Val Arg Val
 -25 -20 -15

Glu Glu Ala Glu Glu Ala Pro Gln Val Tyr Ala Asp Ile Ile Gly Gly
 -10 -5 -1 1 5

10486.204-WO.ST25

Leu Ala Tyr Tyr Met Gly Gly Arg Cys Ser Val Gly Phe Ala Ala Thr
 10 15 20
 Asn Ser Ala Gly Gln Pro Gly Phe Val Thr Ala Gly His Cys Gly Thr
 25 30 35
 Val Gly Thr Gly Val Thr Ile Gly Asn Gly Thr Gly Thr Phe Gln Asn
 40 45 50
 Ser Val Phe Pro Gly Asn Asp Ala Ala Phe Val Arg Gly Thr Ser Asn
 55 60 65 70
 Phe Thr Leu Thr Asn Leu Val Ser Arg Tyr Asn Ser Gly Gly Tyr Gln
 75 80 85
 Ser Val Thr Gly Thr Ser Gln Ala Pro Ala Gly Ser Ala Val Cys Arg
 90 95 100
 Ser Gly Ser Thr Thr Gly Trp His Cys Gly Thr Ile Gln Ala Arg Asn
 105 110 115
 Gln Thr Val Arg Tyr Pro Gln Gly Thr Val Tyr Ser Leu Thr Arg Thr
 120 125 130
 Asn Val Cys Ala Glu Pro Gly Asp Ser Gly Gly Ser Phe Ile Ser Gly
 135 140 145 150
 Ser Gln Ala Gln Gly Val Thr Ser Gly Gly Ser Gly Asn Cys Ser Val
 155 160 165
 Gly Gly Thr Thr Tyr Tyr Gln Glu Val Thr Pro Met Ile Asn Ser Trp
 170 175 180
 Gly Val Arg Ile Arg Thr
 185

<210> 61
 <211> 355
 <212> PRT
 <213> Nocardiosis alba

<220>
 <221> mat_peptide
 <222> (168)..(355)

<400> 61

Ala Thr Gly Pro Leu Pro Gln Ser Pro Thr Pro Asp Glu Ala Glu
 -165 -160 -155

Ala Thr Thr Met Val Glu Ala Leu Gln Arg Asp Leu Gly Leu Ser
 -150 -145 -140

10486.204-WO.ST25

Pro Ser Gln Ala Asp Glu Leu Leu Glu Ala Gln Ala Glu Ser Phe
 -135 -130 -125

Glu Ile Asp Glu Ala Ala Thr Ala Ala Ala Ala Asp Ser Tyr Gly
 -120 -115 -110

Gly Ser Ile Phe Asp Thr Asp Ser Leu Thr Leu Thr Val Leu Val Thr
 -105 -100 -95

Asp Ala Ser Ala Val Glu Ala Val Glu Ala Ala Gly Ala Glu Ala Lys
 -90 -85 -80

Val Val Ser His Gly Met Glu Gly Leu Glu Glu Ile Val Ala Asp Leu
 -75 -70 -65 -60

Asn Ala Ala Asp Ala Gln Pro Gly Val Val Gly Trp Tyr Pro Asp Ile
 -55 -50 -45

His Ser Asp Thr Val Val Leu Glu Val Leu Glu Gly Ser Gly Ala Asp
 -40 -35 -30

Val Asp Ser Leu Leu Ala Asp Ala Gly Val Asp Thr Ala Asp Val Lys
 -25 -20 -15

Val Glu Ser Thr Thr Glu Gln Pro Glu Leu Tyr Ala Asp Ile Ile Gly
 -10 -5 -1 1 5

Gly Leu Ala Tyr Thr Met Gly Gly Arg Cys Ser Val Gly Phe Ala Ala
 10 15 20

Thr Asn Ala Ser Gly Gln Pro Gly Phe Val Thr Ala Gly His Cys Gly
 25 30 35

Thr Val Gly Thr Pro Val Ser Ile Gly Asn Gly Gln Gly Val Phe Glu
 40 45 50

Arg Ser Val Phe Pro Gly Asn Asp Ser Ala Phe Val Arg Gly Thr Ser
 55 60 65

Asn Phe Thr Leu Thr Asn Leu Val Ser Arg Tyr Asn Thr Gly Gly Tyr
 70 75 80 85

Ala Thr Val Ser Gly Ser Ser Gln Ala Ala Ile Gly Ser Gln Ile Cys
 90 95 100

Arg Ser Gly Ser Thr Thr Gly Trp His Cys Gly Thr Val Gln Ala Arg
 105 110 115

Gly Gln Thr Val Ser Tyr Pro Gln Gly Thr Val Gln Asn Leu Thr Arg
 120 125 130

10486.204-WO.ST25

Thr Asn Val Cys Ala Glu Pro Gly Asp Ser Gly Gly Ser Phe Ile Ser
 135 140 145

Gly Ser Gln Ala Gln Gly Val Thr Ser Gly Gly Ser Gly Asn Cys Ser
 150 155 160 165

Phe Gly Gly Thr Thr Tyr Tyr Gln Glu Val Asn Pro Met Leu Ser Ser
 170 175 180

Trp Gly Leu Thr Leu Arg Thr
 185

<210> 62
 <211> 353
 <212> PRT
 <213> Nocardiosis prasina

<220>
 <221> mat_peptide
 <222> (166)..(353)

<400> 62

Ala Thr Gly Pro Leu Pro Gln Ser Pro Thr Pro Glu Ala Asp Ala
 -165 -160 -155

Val Ser Met Gln Glu Ala Leu Gln Arg Asp Leu Gly Leu Thr Pro
 -150 -145 -140

Leu Glu Ala Asp Glu Leu Leu Ala Ala Gln Asp Thr Ala Phe Glu
 -135 -130 -125

Val Asp Glu Ala Ala Ala Ala Ala Ala Gly Asp Ala Tyr Gly Gly
 -120 -115 -110

Ser Val Phe Asp Thr Glu Thr Leu Glu Leu Thr Val Leu Val Thr Asp
 -105 -100 -95 -90

Ala Ala Ser Val Glu Ala Val Glu Ala Thr Gly Ala Gly Thr Glu Leu
 -85 -80 -75

Val Ser Tyr Gly Ile Glu Gly Leu Asp Glu Ile Ile Gln Asp Leu Asn
 -70 -65 -60

Ala Ala Asp Ala Val Pro Gly Val Val Gly Trp Tyr Pro Asp Val Ala
 -55 -50 -45

Gly Asp Thr Val Val Leu Glu Val Leu Glu Gly Ser Gly Ala Asp Val
 -40 -35 -30

Ser Gly Leu Leu Ala Asp Ala Gly Val Asp Ala Ser Ala Val Glu Val
 -25 -20 -15 -10

10486.204-WO.ST25

Thr Ser Ser Ala Gln Pro Glu Leu Tyr Ala Asp Ile Ile Gly Gly Leu
 -5 -1 1 5

Ala Tyr Thr Met Gly Gly Arg Cys Ser Val Gly Phe Ala Ala Thr Asn
 10 15 20

Ala Ala Gly Gln Pro Gly Phe Val Thr Ala Gly His Cys Gly Arg Val
 25 30 35

Gly Thr Gln Val Ser Ile Gly Asn Gly Gln Gly Val Phe Glu Gln Ser
 40 45 50 55

Ile Phe Pro Gly Asn Asp Ala Ala Phe Val Arg Gly Thr Ser Asn Phe
 60 65 70

Thr Leu Thr Asn Leu Val Ser Arg Tyr Asn Thr Gly Gly Tyr Ala Thr
 75 80 85

Val Ala Gly His Asn Gln Ala Pro Ile Gly Ser Ser Val Cys Arg Ser
 90 95 100

Gly Ser Thr Thr Gly Trp His Cys Gly Thr Ile Gln Ala Arg Gly Gln
 105 110 115

Ser Val Ser Tyr Pro Glu Gly Thr Val Thr Asn Met Thr Arg Thr Thr
 120 125 130 135

Val Cys Ala Glu Pro Gly Asp Ser Gly Gly Ser Tyr Ile Ser Gly Asn
 140 145 150

Gln Ala Gln Gly Val Thr Ser Gly Gly Ser Gly Asn Cys Arg Thr Gly
 155 160 165

Gly Thr Thr Phe Tyr Gln Glu Val Thr Pro Met Val Asn Ser Trp Gly
 170 175 180

Val Arg Leu Arg Thr
 185

<210> 63
 <211> 353
 <212> PRT
 <213> Nocardiosis prasina

<220>
 <221> mat_peptide
 <222> (166)..(353)

<400> 63

Ala Thr Gly Pro Leu Pro Gln Ser Pro Thr Pro Glu Ala Asp Ala
 -165 -160 -155

10486.204-WO.ST25

Val Ser Met Gln Glu Ala Leu Gln Arg Asp Leu Gly Leu Thr Pro
 -150 -145 -140

Leu Glu Ala Asp Glu Leu Leu Ala Ala Gln Asp Thr Ala Phe Glu
 -135 -130 -125

Val Asp Glu Ala Ala Ala Glu Ala Ala Gly Asp Ala Tyr Gly Gly
 -120 -115 -110

Ser Val Phe Asp Thr Glu Thr Leu Glu Leu Thr Val Leu Val Thr Asp
 -105 -100 -95 -90

Ser Ala Ala Val Glu Ala Val Glu Ala Thr Gly Ala Gly Thr Glu Leu
 -85 -80 -75

Val Ser Tyr Gly Ile Thr Gly Leu Asp Glu Ile Val Glu Glu Leu Asn
 -70 -65 -60

Ala Ala Asp Ala Val Pro Gly Val Val Gly Trp Tyr Pro Asp Val Ala
 -55 -50 -45

Gly Asp Thr Val Val Leu Glu Val Leu Glu Gly Ser Gly Ala Asp Val
 -40 -35 -30

Gly Gly Leu Leu Ala Asp Ala Gly Val Asp Ala Ser Ala Val Glu Val
 -25 -20 -15 -10

Thr Thr Thr Glu Gln Pro Glu Leu Tyr Ala Asp Ile Ile Gly Gly Leu
 -5 -1 1 5

Ala Tyr Thr Met Gly Gly Arg Cys Ser Val Gly Phe Ala Ala Thr Asn
 10 15 20

Ala Ala Gly Gln Pro Gly Phe Val Thr Ala Gly His Cys Gly Arg Val
 25 30 35

Gly Thr Gln Val Thr Ile Gly Asn Gly Arg Gly Val Phe Glu Gln Ser
 40 45 50 55

Ile Phe Pro Gly Asn Asp Ala Ala Phe Val Arg Gly Thr Ser Asn Phe
 60 65 70

Thr Leu Thr Asn Leu Val Ser Arg Tyr Asn Thr Gly Gly Tyr Ala Thr
 75 80 85

Val Ala Gly His Asn Gln Ala Pro Ile Gly Ser Ser Val Cys Arg Ser
 90 95 100

Gly Ser Thr Thr Gly Trp His Cys Gly Thr Ile Gln Ala Arg Gly Gln
 105 110 115

10486.204-WO.ST25

Ser Val Ser Tyr Pro Glu Gly Thr Val Thr Asn Met Thr Arg Thr Thr
120 125 130 135

Val Cys Ala Glu Pro Gly Asp Ser Gly Gly Ser Tyr Ile Ser Gly Asn
140 145 150

Gln Ala Gln Gly Val Thr Ser Gly Gly Ser Gly Asn Cys Arg Thr Gly
155 160 165

Gly Thr Thr Phe Tyr Gln Glu Val Thr Pro Met Val Asn Ser Trp Gly
170 175 180

Val Arg Leu Arg Thr
185

<210> 64
<211> 439
<212> PRT
<213> Peniophora lycii

<220>
<221> mat_peptide
<222> (31)..(439)

<400> 64

Met Val Ser Ser Ala Phe Ala Pro Ser Ile Leu Leu Ser Leu Met Ser
-30 -25 -20 -15

Ser Leu Ala Leu Ser Thr Gln Phe Ser Phe Val Ala Ala Gln Leu Pro
-10 -5 -1 1

Ile Pro Ala Gln Asn Thr Ser Asn Trp Gly Pro Tyr Asp Pro Phe Phe
5 10 15

Pro Val Glu Pro Tyr Ala Ala Pro Pro Glu Gly Cys Thr Val Thr Gln
20 25 30

Val Asn Leu Ile Gln Arg His Gly Ala Arg Trp Pro Thr Ser Gly Ala
35 40 45 50

Arg Ser Arg Gln Val Ala Ala Val Ala Lys Ile Gln Met Ala Arg Pro
55 60 65

Phe Thr Asp Pro Lys Tyr Glu Phe Leu Asn Asp Phe Val Tyr Lys Phe
70 75 80

Gly Val Ala Asp Leu Leu Pro Phe Gly Ala Asn Gln Ser His Gln Thr
85 90 95

Gly Thr Asp Met Tyr Thr Arg Tyr Ser Thr Leu Phe Glu Gly Gly Asp
100 105 110

10486.204-WO.ST25

Val Pro Phe Val Arg Ala Ala Gly Asp Gln Arg Val Val Asp Ser Ser
 115 120 125 130

Thr Asn Trp Thr Ala Gly Phe Gly Asp Ala Ser Gly Glu Thr Val Leu
 135 140 145

Pro Thr Leu Gln Val Val Leu Gln Glu Gly Asn Cys Thr Leu Cys
 150 155 160

Asn Asn Met Cys Pro Asn Glu Val Asp Gly Asp Glu Ser Thr Thr Trp
 165 170 175

Leu Gly Val Phe Ala Pro Asn Ile Thr Ala Arg Leu Asn Ala Ala Ala
 180 185 190

Pro Ser Ala Asn Leu Ser Asp Ser Asp Ala Leu Thr Leu Met Asp Met
 195 200 205 210

Cys Pro Phe Asp Thr Leu Ser Ser Gly Asn Ala Ser Pro Phe Cys Asp
 215 220 225

Leu Phe Thr Ala Glu Glu Tyr Val Ser Tyr Glu Tyr Tyr Tyr Asp Leu
 230 235 240

Asp Lys Tyr Tyr Gly Thr Gly Pro Gly Asn Ala Leu Gly Pro Val Gln
 245 250 255

Gly Val Gly Tyr Val Asn Glu Leu Leu Ala Arg Leu Thr Gly Gln Ala
 260 265 270

Val Arg Asp Glu Thr Gln Thr Asn Arg Thr Leu Asp Ser Asp Pro Ala
 275 280 285 290

Thr Phe Pro Leu Asn Arg Thr Phe Tyr Ala Asp Phe Ser His Asp Asn
 295 300 305

Thr Met Val Pro Ile Phe Ala Ala Leu Gly Leu Phe Asn Ala Thr Ala
 310 315 320

Leu Asp Pro Leu Lys Pro Asp Glu Asn Arg Leu Trp Val Asp Ser Lys
 325 330 335

Leu Val Pro Phe Ser Gly His Met Thr Val Glu Lys Leu Ala Cys Ser
 340 345 350

Gly Lys Glu Ala Val Arg Val Leu Val Asn Asp Ala Val Gln Pro Leu
 355 360 365 370

Glu Phe Cys Gly Gly Val Asp Gly Val Cys Glu Leu Ser Ala Phe Val
 375 380 385

10486.204-WO.ST25

Glu Ser Gln Thr Tyr Ala Arg Glu Asn Gly Gln Gly Asp Phe Ala Lys
 390 395 400

Cys Gly Phe Val Pro Ser Glu
 405

<210> 65
 <211> 39
 <212> PRT
 <213> Artificial

<220>
 <223> Peptide

<220>
 <221> PEPTIDE
 <222> (1)..(39)

<400> 65

Arg Arg Arg Pro Arg Pro Pro Tyr Leu Pro Arg Pro Arg Pro Pro Pro
 1 5 10 15

Phe Phe Pro Pro Arg Leu Pro Pro Arg Ile Pro Pro Gly Phe Pro Pro
 20 25 30

Arg Phe Pro Pro Arg Phe Pro
 35

<210> 66
 <211> 44
 <212> DNA
 <213> Artificial

<220>
 <223> Primer

<220>
 <221> misc_feature
 <223> Primer

<400> 66
 catagcacca tggaaaggag acgtccccga ccccatatt tgcc

44

<210> 67
 <211> 47
 <212> DNA
 <213> Artificial

<220>
 <223> Primer

<220>
 <221> misc_feature
 <223> Primer

<400> 67

10486.204-wo.ST25
catagcacca tggatgaaag gagacgtccc cgacccccat atttgcc 47

<210> 68
<211> 50
<212> DNA
<213> Artificial

<220>
<223> Primer

<220>
<221> misc_feature
<223> Primer

<400> 68
catagcacca tggacgatga aaggagacgt ccccgacccc catatttgcc 50

<210> 69
<211> 53
<212> DNA
<213> Artificial

<220>
<223> Primer

<220>
<221> misc_feature
<223> Primer

<400> 69
catagcacca tggatgacga tgaaggaga cgtccccgac ccccatattt gcc 53

<210> 70
<211> 56
<212> DNA
<213> Artificial

<220>
<223> Primer

<220>
<221> misc_feature
<223> Primer

<400> 70
catagcacca tggacgatga cgatgaaagg agacgtcccc gacccccata tttgcc 56

<210> 71
<211> 23
<212> DNA
<213> Artificial

<220>
<223> Primer

<220>
<221> misc_feature
<223> Primer

<400> 71

10486.204-WO.ST25

ccataagatt agcggatcct acc

23

<210> 72
 <211> 21
 <212> DNA
 <213> Artificial

<220>
 <223> Primer

<220>
 <221> misc_feature
 <223> Primer

<400> 72
 ctctcatccg ccaaaacagc c

21

<210> 73
 <211> 18
 <212> PRT
 <213> Artificial

<220>
 <223> Peptide

<220>
 <221> PEPTIDE
 <222> (1)..(18)

<400> 73

Lys Asn Leu Arg Arg Ile Ile Arg Lys Gly Ile His Ile Ile Lys Lys
 1 5 10 15

Tyr Gly

<210> 74
 <211> 51
 <212> DNA
 <213> Artificial

<220>
 <223> Primer

<220>
 <221> misc_feature
 <223> Primer

<400> 74
 aggggtatcg atggctaaga gagaagccga aaggagacgt ccccgacccc c

51

<210> 75
 <211> 54
 <212> DNA
 <213> Artificial

<220>
 <223> Primer

10486.204-WO.ST25

<220>
 <221> misc_feature
 <223> Primer

 <400> 75
 aggggtatcg atggctaaga gagaagccga tgaaaggaga cgtccccgac cccc 54

 <210> 76
 <211> 57
 <212> DNA
 <213> Artificial

 <220>
 <223> Primer

 <220>
 <221> misc_feature
 <223> Primer

 <400> 76
 aggggtatcg atggctaaga gagaagccga cgatgaaagg agacgtcccc gaccccc 57

 <210> 77
 <211> 60
 <212> DNA
 <213> Artificial

 <220>
 <223> Primer

 <220>
 <221> misc_feature
 <223> Primer

 <400> 77
 aggggtatcg atggctaaga gagaagccga tgacgatgaa aggagacgtc cccgaccccc 60

 <210> 78
 <211> 63
 <212> DNA
 <213> Artificial

 <220>
 <223> Primer

 <220>
 <221> misc_feature
 <223> Primer

 <400> 78
 aggggtatcg atggctaaga gagaagccga cgatgacgat gaaaggagac gtccccgacc 60
 ccc 63

 <210> 79
 <211> 4
 <212> PRT
 <213> Artificial

 <220>

10486.204-WO.ST25

<223> Peptide

<220>

<221> MISC_FEATURE

<223> Linker

<400> 79

Pro Glu Pro Thr

1

<210> 80

<211> 4

<212> PRT

<213> Artificial

<220>

<223> Peptide

<220>

<221> MISC_FEATURE

<223> Linker

<400> 80

Glu Pro Thr Pro

1

<210> 81

<211> 4

<212> PRT

<213> Artificial

<220>

<223> Peptide

<220>

<221> MISC_FEATURE

<223> Linker

<400> 81

Pro Thr Glu Pro

1

<210> 82

<211> 4

<212> PRT

<213> Artificial

<220>

<223> Peptide

<220>

<221> MISC_FEATURE

<223> Linker

<400> 82

Thr Pro Glu Pro

1

10486.204-WO.ST25

<210> 83
<211> 4
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> MISC_FEATURE
<223> linker

<400> 83

Ile Glu Gly Arg
1

<210> 84
<211> 8
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> MISC_FEATURE
<223> Extension

<400> 84

Gln Ser His Val Gln Ser Ala Pro
1 5

<210> 85
<211> 4
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> MISC_FEATURE
<223> Extension

<400> 85

Gln Ser Ala Pro
1

<210> 86
<211> 6
<212> PRT
<213> Artificial

<220>
<223> Peptide

10486.204-WO.ST25

<220>
<221> MISC_FEATURE
<223> Cleavage linker

<220>
<221> misc_feature
<222> (1)..(1)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa can be any naturally occurring amino acid

<400> 86

Xaa Asp Asp Asp Lys Xaa
1 5

<210> 87
<211> 4
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> MISC_FEATURE
<223> Cleavage linker

<220>
<221> misc_feature
<222> (1)..(1)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (4)..(4)
<223> Xaa can be any naturally occurring amino acid

<400> 87

Xaa Lys Arg Xaa
1

<210> 88
<211> 6
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> MISC_FEATURE
<223> Cleavage linker

<220>
<221> misc_feature
<222> (1)..(1)
<223> Xaa can be any naturally occurring amino acid

<220>

10486.204-WO.ST25

<221> misc_feature
 <222> (6)..(6)
 <223> Xaa can be any naturally occurring amino acid
 <400> 88

Xaa Ile Glu Gly Arg Xaa
 1 5

<210> 89
 <211> 6
 <212> PRT
 <213> Artificial

<220>
 <223> Peptide

<220>
 <221> MISC_FEATURE
 <223> Cleavage linker

<220>
 <221> misc_feature
 <222> (2)..(2)
 <223> Xaa can be any naturally occurring amino acid

<220>
 <221> misc_feature
 <222> (5)..(6)
 <223> Xaa can be any naturally occurring amino acid

<400> 89

Pro Xaa Gly Pro Xaa Xaa
 1 5

<210> 90
 <211> 8
 <212> PRT
 <213> Artificial

<220>
 <223> Peptide

<220>
 <221> MISC_FEATURE
 <223> Cleavage linker

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Xaa can be any naturally occurring amino acid

<220>
 <221> misc_feature
 <222> (8)..(8)
 <223> Xaa can be any naturally occurring amino acid

<400> 90

Xaa Gly Val Arg Gly Pro Arg Xaa
 1 5

10486.204-WO.ST25

<210> 91
<211> 4
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> MISC_FEATURE
<223> Cleavage linker

<220>
<221> misc_feature
<222> (4)..(4)
<223> Xaa can be any naturally occurring amino acid

<400> 91

Ser Asn Gly Xaa
1

<210> 92
<211> 5
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> MISC_FEATURE
<223> Protection peptide

<400> 92

Asp Asp Glu Glu Glu
1 5

<210> 93
<211> 5
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> MISC_FEATURE
<223> Protection Peptide

<400> 93

Asp Asp Asp Glu Glu
1 5

<210> 94
<211> 5
<212> PRT
<213> Artificial

<220>

10486.204-WO.ST25

<223> Peptide

<220>

<221> MISC_FEATURE

<223> Protection peptide

<400> 94

Asp Asp Asp Asp Glu
1 5

<210> 95

<211> 5

<212> PRT

<213> Artificial

<220>

<223> Peptide

<220>

<221> MISC_FEATURE

<223> Protection peptide

<400> 95

Glu Glu Asp Asp Glu
1 5

<210> 96

<211> 5

<212> PRT

<213> Artificial

<220>

<223> Peptide

<220>

<221> MISC_FEATURE

<223> Protection peptide

<400> 96

Asp Asp Glu Glu Asp
1 5

<210> 97

<211> 5

<212> PRT

<213> Artificial

<220>

<223> Peptide

<220>

<221> MISC_FEATURE

<223> Protection peptide

<400> 97

Glu Asp Glu Asp Glu
1 5

10486.204-WO.ST25

<210> 98
<211> 6
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> MISC_FEATURE
<223> Protection peptide

<400> 98

Asp Asp Asp Glu Glu Glu
1 5

<210> 99
<211> 6
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> MISC_FEATURE
<223> Protection peptide

<400> 99

Asp Glu Asp Glu Asp Glu
1 5

<210> 100
<211> 6
<212> PRT
<213> Artificial

<220>
<223> Peptide

<220>
<221> MISC_FEATURE
<223> Protection peptide

<400> 100

Glu Glu Asp Asp Glu Glu
1 5

<210> 101
<211> 6
<212> PRT
<213> Artificial

<220>
<223> Peptide

10486.204-WO.ST25

<220>

<221> MISC_FEATURE

<223> Protection peptide

<400> 101

Asp Asp Asp Asp Asp Pro

1

5

<210> 102

<211> 7

<212> PRT

<213> Artificial

<220>

<223> Peptide

<220>

<221> MISC_FEATURE

<223> Protection peptide

<400> 102

Glu Glu Glu Glu Glu Asp Pro

1

5

<210> 103

<211> 4

<212> PRT

<213> Artificial

<220>

<223> Peptide

<220>

<221> MISC_FEATURE

<223> Protection peptide

<400> 103

Asp Asp Asp Glu

1

<210> 104

<211> 8

<212> PRT

<213> Artificial

<220>

<223> Peptide

<220>

<221> MISC_FEATURE

<223> Protection peptide

<400> 104

Asp Glu Asp Glu Asp Glu Asp Pro

1

5

<210> 105

10486.204-WO.ST25

<211> 14
 <212> PRT
 <213> Artificial

<220>
 <223> Peptide

<220>
 <221> MISC_FEATURE
 <223> Protection peptide

<400> 105

Asp Asp Asp Gly Gly Glu Glu Glu Gly Gly Asp Asp Asp Pro
 1 5 10

<210> 106
 <211> 14
 <212> PRT
 <213> Artificial

<220>
 <223> Peptide

<220>
 <221> MISC_FEATURE
 <223> Protection peptide

<400> 106

Asp Asp Asp Gly Gly Asp Asp Asp Pro Pro Asp Asp Asp Glu
 1 5 10

<210> 107
 <211> 31
 <212> DNA
 <213> Artificial

<220>
 <223> Primer

<400> 107
 tatagagctc cattgaaagg ggaggagaat c

31

<210> 108
 <211> 33
 <212> DNA
 <213> Artificial

<220>
 <223> Primer

<400> 108
 tataactgcag aatgaggcag caagaagatg agc

33

<210> 109
 <211> 33
 <212> DNA
 <213> Artificial

<220>
 <223> Primer

10486.204-wo.ST25

<400> 109
tatactgcag ccgcggcagc ttctgcctta aac 33

<210> 110
<211> 32
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 110
tatagctagc tggattgatt ttgccgactc cg 32

<210> 111
<211> 1227
<212> DNA
<213> Artificial

<220>
<223> DNA fragment (PP1223-9 Sac1 Mlu1)

<220>
<221> CDS
<222> (28)..(1218)

<220>
<221> misc_feature
<222> (115)..(1056)
<223> Pectate lyase

<220>
<221> mat_peptide
<222> (115)..()

<220>
<221> misc_feature
<222> (1066)..(1218)
<223> AFP

<400> 111
gagctccatt gaaaggggag gagaatc atg aaa caa caa aaa cgg ctt tac gcc 54
Met Lys Gln Gln Lys Arg Leu Tyr Ala
-25

cga ttg ctg acg ctg tta ttt gcg ctc atc ttc ttg ctg cct cat tct 102
Arg Leu Leu Thr Leu Leu Phe Ala Leu Ile Phe Leu Leu Pro His Ser
-20 -15 -10 -5

gca gcc gcg gca gct tct gcc tta aac tcg ggc aaa gta aat ccg ctt 150
Ala Ala Ala Ala Ala Ser Ala Leu Asn Ser Gly Lys Val Asn Pro Leu
-1 1 5 10

gcc gac ttc agc tta aaa ggc ttt gcc gca cta aac ggc gga aca acg 198
Ala Asp Phe Ser Leu Lys Gly Phe Ala Ala Leu Asn Gly Gly Thr Thr
15 20 25

ggc gga gaa ggc ggt cag acg gta acc gta aca acg gga gat cag ctg 246
Gly Gly Glu Gly Gly Gln Thr Val Thr Val Thr Thr Gly Asp Gln Leu
30 35 40

att gcg gca tta aaa aat aag aat gca aat acg cct tta aaa att tat 294
Ile Ala Ala Leu Lys Asn Lys Asn Ala Asn Thr Pro Leu Lys Ile Tyr
45 50 55 60

10486.204-WO.ST25

gtc aac ggc acc att aca aca tca aat aca tcc gca tca aag att gac Val Asn Gly Thr Ile Thr Thr Ser Asn Thr Ser Ala Ser Lys Ile Asp 65 70 75	342
gtc aaa gac gtg tca aac gta tcg att gtc gga tca ggg acc aaa ggg Val Lys Asp Val Ser Asn Val Ser Ile Val Gly Ser Gly Thr Lys Gly 80 85 90	390
gaa ctc aaa ggg atc ggc atc aaa ata tgg cgg gcc aac aac atc atc Glu Leu Lys Gly Ile Gly Ile Lys Ile Trp Arg Ala Asn Asn Ile Ile 95 100 105	438
atc cgc aac ttg aaa att cac gag gtc gcc tca ggc gat aaa gac gcg Ile Arg Asn Leu Lys Ile His Glu Val Ala Ser Gly Asp Lys Asp Ala 110 115 120	486
atc ggc att gaa ggc cct tct aaa aac att tgg gtt gat cat aat gag Ile Gly Ile Glu Gly Pro Ser Lys Asn Ile Trp Val Asp His Asn Glu 125 130 135 140	534
ctt tac cac agc ctg aac gtt gac aaa gat tac tat gac gga tta ttt Leu Tyr His Ser Leu Asn Val Asp Lys Asp Tyr Tyr Asp Gly Leu Phe 145 150 155	582
gac gtc aaa aga gat gcg gaa tat att aca ttc tct tgg aac tat gtg Asp Val Lys Arg Asp Ala Glu Tyr Ile Thr Phe Ser Trp Asn Tyr Val 160 165 170	630
cac gat gga tgg aaa tca atg ctg atg ggt tca tcg gac agc gat aat His Asp Gly Trp Lys Ser Met Leu Met Gly Ser Ser Asp Ser Asp Asn 175 180 185	678
tac aac agg acg att aca ttc cat cat aac tgg ttt gag aat ctg aat Tyr Asn Arg Thr Ile Thr Phe His His Asn Trp Phe Glu Asn Leu Asn 190 195 200	726
tcg cgt gtg ccg tca ttc cgt ttc gga gaa ggc cat att tac aac aac Ser Arg Val Pro Ser Phe Arg Phe Gly Glu Gly His Ile Tyr Asn Asn 205 210 215 220	774
tat ttc aat aaa atc atc gac agc gga att aat tcg agg atg ggc gcg Tyr Phe Asn Lys Ile Ile Asp Ser Gly Ile Asn Ser Arg Met Gly Ala 225 230 235	822
cgc atc aga att gag aac aac ctc ttt gaa aac gcc aaa gat ccg att Arg Ile Arg Ile Glu Asn Asn Leu Phe Glu Asn Ala Lys Asp Pro Ile 240 245 250	870
gtc tct tgg tac agc agt tca ccg ggc tat tgg cat gta tcc aac aac Val Ser Trp Tyr Ser Ser Ser Pro Gly Tyr Trp His Val Ser Asn Asn 255 260 265	918
aaa ttt gta aac tct agg ggc agt atg ccg act acc tct act aca acc Lys Phe Val Asn Ser Arg Gly Ser Met Pro Thr Thr Ser Thr Thr Thr 270 275 280	966
tat aat ccg cca tac agc tac tca ctc gac aat gtc gac aat gta aaa Tyr Asn Pro Pro Tyr Ser Tyr Ser Leu Asp Asn Val Asp Asn Val Lys 285 290 300	1014
tca atc gtc aag caa aat gcc gga gtc ggc aaa atc aat cca gct agc Ser Ile Val Lys Gln Asn Ala Gly Val Gly Lys Ile Asn Pro Ala Ser 305 310 315	1062
gaa gcc acc tac ccc ggc aag tgc tac aag aag gac aac atc tgc aag Glu Ala Thr Tyr Pro Gly Lys Cys Tyr Lys Lys Asp Asn Ile Cys Lys 320 325 330	1110

10486.204-wo.ST25

tac aag gcc cag tcc ggc aag acc ggc atc tgc aag tgc tac gtc aag 1158
 Tyr Lys Ala Gln Ser Gly Lys Thr Gly Ile Cys Lys Cys Tyr Val Lys
 335 340 345

cgc tgc ccc cgc gac ggc gcc aag tgc gac ctc gac tcc tac aag ggc 1206
 Arg Cys Pro Arg Asp Gly Ala Lys Cys Asp Leu Asp Ser Tyr Lys Gly
 350 355 360

aag tgc cac tgc tagacgcgt 1227
 Lys Cys His Cys
 365

<210> 112
 <211> 397
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic Construct

<400> 112

Met Lys Gln Gln Lys Arg Leu Tyr Ala Arg Leu Leu Thr Leu Leu Phe
 -25 -20 -15

Ala Leu Ile Phe Leu Leu Pro His Ser Ala Ala Ala Ala Ala Ser Ala
 -10 -5 -1 1

Leu Asn Ser Gly Lys Val Asn Pro Leu Ala Asp Phe Ser Leu Lys Gly
 5 10 15

Phe Ala Ala Leu Asn Gly Gly Thr Thr Gly Gly Glu Gly Gly Gln Thr
 20 25 30 35

Val Thr Val Thr Thr Gly Asp Gln Leu Ile Ala Ala Leu Lys Asn Lys
 40 45 50

Asn Ala Asn Thr Pro Leu Lys Ile Tyr Val Asn Gly Thr Ile Thr Thr
 55 60 65

Ser Asn Thr Ser Ala Ser Lys Ile Asp Val Lys Asp Val Ser Asn Val
 70 75 80

Ser Ile Val Gly Ser Gly Thr Lys Gly Glu Leu Lys Gly Ile Gly Ile
 85 90 95

Lys Ile Trp Arg Ala Asn Asn Ile Ile Ile Arg Asn Leu Lys Ile His
 100 105 110 115

Glu Val Ala Ser Gly Asp Lys Asp Ala Ile Gly Ile Glu Gly Pro Ser
 120 125 130

Lys Asn Ile Trp Val Asp His Asn Glu Leu Tyr His Ser Leu Asn Val
 135 140 145

10486.204-wo.ST25

Asp Lys Asp Tyr Tyr Asp Gly Leu Phe Asp Val Lys Arg Asp Ala Glu
 150 155 160

Tyr Ile Thr Phe Ser Trp Asn Tyr Val His Asp Gly Trp Lys Ser Met
 165 170 175

Leu Met Gly Ser Ser Asp Ser Asp Asn Tyr Asn Arg Thr Ile Thr Phe
 180 185 190 195

His His Asn Trp Phe Glu Asn Leu Asn Ser Arg Val Pro Ser Phe Arg
 200 205 210

Phe Gly Glu Gly His Ile Tyr Asn Asn Tyr Phe Asn Lys Ile Ile Asp
 215 220 225

Ser Gly Ile Asn Ser Arg Met Gly Ala Arg Ile Arg Ile Glu Asn Asn
 230 235 240

Leu Phe Glu Asn Ala Lys Asp Pro Ile Val Ser Trp Tyr Ser Ser Ser
 245 250 255

Pro Gly Tyr Trp His Val Ser Asn Asn Lys Phe Val Asn Ser Arg Gly
 260 265 270 275

Ser Met Pro Thr Thr Ser Thr Thr Thr Tyr Asn Pro Pro Tyr Ser Tyr
 280 285 290

Ser Leu Asp Asn Val Asp Asn Val Lys Ser Ile Val Lys Gln Asn Ala
 295 300 305

Gly Val Gly Lys Ile Asn Pro Ala Ser Glu Ala Thr Tyr Pro Gly Lys
 310 315 320

Cys Tyr Lys Lys Asp Asn Ile Cys Lys Tyr Lys Ala Gln Ser Gly Lys
 325 330 335

Thr Gly Ile Cys Lys Cys Tyr Val Lys Arg Cys Pro Arg Asp Gly Ala
 340 345 350 355

Lys Cys Asp Leu Asp Ser Tyr Lys Gly Lys Cys His Cys
 360 365

<210> 113
 <211> 26
 <212> DNA
 <213> Artificial

<220>
 <223> Primer

<400> 113
 tataacgcgt ctagcagtgg cacttg

10486.204-wo.ST25

<210> 114
 <211> 1297
 <212> DNA
 <213> Artificial

<220>
 <223> DNA fragment (PP1331-2 Sac1 Mlu1)

<220>
 <221> CDS
 <222> (27)..(1289)

<220>
 <221> mat_peptide
 <222> (114)..(1289)

<220>
 <221> misc_feature
 <222> (114)..(1055)
 <223> Pectate lyase

<220>
 <221> misc_feature
 <222> (1236)..(1289)
 <223> G10 novispirin

<400> 114
 gagctcattg aaaggggagg agaatc atg aaa caa caa aaa cgg ctt tac gcc 53
 Met Lys Gln Gln Lys Arg Leu Tyr Ala
 -25

cga ttg ctg acg ctg tta ttt gcg ctc atc ttc ttg ctg cct cat tct 101
 Arg Leu Leu Thr Leu Leu Phe Ala Leu Ile Phe Leu Leu Pro His Ser
 -20 -15 -10 -5

gca gcc gcg gca gct tct gcc tta aac tcg ggc aaa gta aat ccg ctt 149
 Ala Ala Ala Ala Ala Ser Ala Leu Asn Ser Gly Lys Val Asn Pro Leu
 -1 1 5 10

gcc gac ttc agc tta aaa ggc ttt gcc gca cta aac ggc gga aca acg 197
 Ala Asp Phe Ser Leu Lys Gly Phe Ala Ala Leu Asn Gly Gly Thr Thr
 15 20 25

ggc gga gaa ggc ggt cag acg gta acc gta aca acg gga gat cag ctg 245
 Gly Gly Glu Gly Gly Gln Thr Val Thr Val Thr Thr Gly Asp Gln Leu
 30 35 40

att gcg gca tta aaa aat aag aat gca aat acg cct tta aaa att tat 293
 Ile Ala Ala Leu Lys Asn Lys Asn Ala Asn Thr Pro Leu Lys Ile Tyr
 45 50 55 60

gtc aac ggc acc att aca aca tca aat aca tcc gca tca aag att gac 341
 Val Asn Gly Thr Ile Thr Thr Ser Asn Thr Ser Ala Ser Lys Ile Asp
 65 70 75

gtc aaa gac gtg tca aac gta tcg att gtc gga tca ggg acc aaa ggg 389
 Val Lys Asp Val Ser Asn Val Ser Ile Val Gly Ser Gly Thr Lys Gly
 80 85 90

gaa ctc aaa ggg atc ggc atc aaa ata tgg cgg gcc aat aac atc atc 437
 Glu Leu Lys Gly Ile Gly Ile Lys Ile Trp Arg Ala Asn Asn Ile Ile
 95 100 105

atc cgc aac ttg aaa att cac gag gtc gcc tca ggc gat aaa gac gcg 485
 Ile Arg Asn Leu Lys Ile His Glu Val Ala Ser Gly Asp Lys Asp Ala
 110 115 120

10486.204-WO.ST25																
atc	ggc	att	gaa	ggc	cct	tct	aaa	aac	att	tgg	ggt	gat	cat	aat	gag	533
Ile	Gly	Ile	Glu	Gly	Pro	Ser	Lys	Asn	Ile	Trp	Val	Asp	His	Asn	Glu	
125					130					135					140	
ctt	tac	cac	agc	ctg	aac	gtt	gac	aaa	gat	tac	tat	gac	gga	tta	ttt	581
Leu	Tyr	His	Ser	Leu	Asn	Val	Asp	Lys	Asp	Tyr	Tyr	Asp	Gly	Leu	Phe	
				145					150					155		
gac	gtc	aaa	aga	gat	gcg	gaa	tat	att	aca	ttc	tct	tgg	aac	tat	gtg	629
Asp	Val	Lys	Arg	Asp	Ala	Glu	Tyr	Ile	Thr	Phe	Ser	Trp	Asn	Tyr	Val	
			160					165					170			
cac	gat	gga	tgg	aaa	tca	atg	ctg	atg	ggt	tca	tcg	gac	agc	gat	aat	677
His	Asp	Gly	Trp	Lys	Ser	Met	Leu	Met	Gly	Ser	Ser	Asp	Ser	Asp	Asn	
		175					180					185				
tac	aac	agg	acg	att	aca	ttc	cat	cat	aac	tgg	ttt	gag	aat	ctg	aat	725
Tyr	Asn	Arg	Thr	Ile	Thr	Phe	His	His	Asn	Trp	Phe	Glu	Asn	Leu	Asn	
	190					195					200					
tcg	cg	gtg	tcg	tca	ttc	cg	ttc	gga	gaa	ggc	cat	att	tac	aac	aac	773
Ser	Arg	Val	Ser	Ser	Phe	Arg	Phe	Gly	Glu	Gly	His	Ile	Tyr	Asn	Asn	
205					210					215					220	
tat	ttc	aat	aaa	atc	atc	gac	agc	gga	att	aat	tcg	agg	atg	ggc	gcg	821
Tyr	Phe	Asn	Lys	Ile	Ile	Asp	Ser	Gly	Ile	Asn	Ser	Arg	Met	Gly	Ala	
				225					230					235		
cg	atc	aga	att	gag	aac	aac	ctc	ttt	gaa	aac	gcc	aaa	gat	ccg	att	869
Arg	Ile	Arg	Ile	Glu	Asn	Asn	Leu	Phe	Glu	Asn	Ala	Lys	Asp	Pro	Ile	
			240					245					250			
gtc	tct	tgg	tac	agc	agt	tca	ccg	ggc	tat	tgg	cat	gta	tcc	aac	aac	917
Val	Ser	Trp	Tyr	Ser	Ser	Ser	Pro	Gly	Tyr	Trp	His	Val	Ser	Asn	Asn	
		255					260					265				
aaa	ttt	gta	aac	tct	agg	ggc	agt	atg	ccg	act	acc	tct	act	aca	acc	965
Lys	Phe	Val	Asn	Ser	Arg	Gly	Ser	Met	Pro	Thr	Thr	Ser	Thr	Thr	Thr	
	270					275					280					
tat	aat	ccg	cca	tac	agc	tac	tca	ctc	gac	aat	gtc	gac	aat	gta	aaa	1013
Tyr	Asn	Pro	Pro	Tyr	Ser	Tyr	Ser	Leu	Asp	Asn	Val	Asp	Asn	Val	Lys	
285					290				295						300	
tca	atc	gtc	aag	caa	aat	gcc	gga	gtc	ggc	aaa	atc	aat	cca	gct	agc	1061
Ser	Ile	Val	Lys	Gln	Asn	Ala	Gly	Val	Gly	Lys	Ile	Asn	Pro	Ala	Ser	
				305					310					315		
ttg	gat	aaa	aga	gag	gct	gaa	gct	tgt	gag	gaa	gag	aga	aat	gca	gaa	1109
Leu	Asp	Lys	Arg	Glu	Ala	Glu	Ala	Cys	Glu	Glu	Glu	Arg	Asn	Ala	Glu	
			320					325					330			
gaa	gaa	aga	aga	gat	gaa	cca	gat	gaa	agg	gat	gct	caa	gtg	gaa	cat	1157
Glu	Glu	Arg	Arg	Asp	Glu	Pro	Asp	Glu	Arg	Asp	Ala	Gln	Val	Glu	His	
				335			340					345				
aat	gcg	cg	gag	gct	gaa	gct	gat	gcg	gaa	gcg	gtg	ggc	ccg	gaa	gcg	1205
Asn	Ala	Arg	Glu	Ala	Glu	Ala	Asp	Ala	Glu	Ala	Val	Gly	Pro	Glu	Ala	
	350					355					360					
ttt	gcg	gat	gaa	gat	ctg	gat	cca	tgg	gaa	aag	aac	ctc	aga	cga	atc	1253
Phe	Ala	Asp	Glu	Asp	Leu	Asp	Pro	Trp	Glu	Lys	Asn	Leu	Arg	Arg	Ile	
365					370					375					380	
ata	agg	aaa	ggt	ata	cac	atc	att	aag	aaa	tac	gga	taacgcgt				1297
Ile	Arg	Lys	Gly	Ile	His	Ile	Ile	Lys	Lys	Tyr	Gly					
				385					390							

10486.204-WO.ST25

<210> 115
 <211> 421
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic Construct

<400> 115

Met Lys Gln Gln Lys Arg Leu Tyr Ala Arg Leu Leu Thr Leu Leu Phe
 -25 -20 -15

Ala Leu Ile Phe Leu Leu Pro His Ser Ala Ala Ala Ala Ala Ser Ala
 -10 -5 -1 1

Leu Asn Ser Gly Lys Val Asn Pro Leu Ala Asp Phe Ser Leu Lys Gly
 5 10 15

Phe Ala Ala Leu Asn Gly Gly Thr Thr Gly Gly Glu Gly Gly Gln Thr
 20 25 30 35

Val Thr Val Thr Thr Gly Asp Gln Leu Ile Ala Ala Leu Lys Asn Lys
 40 45 50

Asn Ala Asn Thr Pro Leu Lys Ile Tyr Val Asn Gly Thr Ile Thr Thr
 55 60 65

Ser Asn Thr Ser Ala Ser Lys Ile Asp Val Lys Asp Val Ser Asn Val
 70 75 80

Ser Ile Val Gly Ser Gly Thr Lys Gly Glu Leu Lys Gly Ile Gly Ile
 85 90 95

Lys Ile Trp Arg Ala Asn Asn Ile Ile Ile Arg Asn Leu Lys Ile His
 100 105 110 115

Glu Val Ala Ser Gly Asp Lys Asp Ala Ile Gly Ile Glu Gly Pro Ser
 120 125 130

Lys Asn Ile Trp Val Asp His Asn Glu Leu Tyr His Ser Leu Asn Val
 135 140 145

Asp Lys Asp Tyr Tyr Asp Gly Leu Phe Asp Val Lys Arg Asp Ala Glu
 150 155 160

Tyr Ile Thr Phe Ser Trp Asn Tyr Val His Asp Gly Trp Lys Ser Met
 165 170 175

Leu Met Gly Ser Ser Asp Ser Asp Asn Tyr Asn Arg Thr Ile Thr Phe
 180 185 190 195

His His Asn Trp Phe Glu Asn Leu Asn Ser Arg Val Ser Ser Phe Arg

10486.204-WO.ST25
205

200

210

Phe Gly Glu Gly His Ile Tyr Asn Asn Tyr Phe Asn Lys Ile Ile Asp
215 220 225

Ser Gly Ile Asn Ser Arg Met Gly Ala Arg Ile Arg Ile Glu Asn Asn
230 235 240

Leu Phe Glu Asn Ala Lys Asp Pro Ile Val Ser Trp Tyr Ser Ser Ser
245 250 255

Pro Gly Tyr Trp His Val Ser Asn Asn Lys Phe Val Asn Ser Arg Gly
260 265 270 275

Ser Met Pro Thr Thr Ser Thr Thr Thr Tyr Asn Pro Pro Tyr Ser Tyr
280 285 290

Ser Leu Asp Asn Val Asp Asn Val Lys Ser Ile Val Lys Gln Asn Ala
295 300 305

Gly Val Gly Lys Ile Asn Pro Ala Ser Leu Asp Lys Arg Glu Ala Glu
310 315 320

Ala Cys Glu Glu Glu Arg Asn Ala Glu Glu Glu Arg Arg Asp Glu Pro
325 330 335

Asp Glu Arg Asp Ala Gln Val Glu His Asn Ala Arg Glu Ala Glu Ala
340 345 350 355

Asp Ala Glu Ala Val Gly Pro Glu Ala Phe Ala Asp Glu Asp Leu Asp
360 365 370

Pro Trp Glu Lys Asn Leu Arg Arg Ile Ile Arg Lys Gly Ile His Ile
375 380 385

Ile Lys Lys Tyr Gly
390

<210> 116
<211> 28
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 116
tataacgcgt tatccgtatt tcttaatg

28

<210> 117
<211> 53
<212> PRT
<213> Artificial

10486.204-WO.ST25

<220>

<223> Peptide

<220>

<221> MISC_FEATURE

<222> (1)..(5)

<223> Quenching domain

<220>

<221> MISC_FEATURE

<222> (6)..(14)

<223> Linker

<220>

<221> MISC_FEATURE

<222> (15)..()

<223> PR39

<400> 117

Asp Asp Asp Asp Glu Gly Gly Gly Gly Gly Gly Gly Gly Glu Arg Arg
1 5 10 15

Arg Pro Arg Pro Pro Tyr Leu Pro Arg Pro Arg Pro Pro Pro Phe Phe
20 25 30

Pro Pro Arg Leu Pro Pro Arg Ile Pro Pro Gly Phe Pro Pro Arg Phe
35 40 45

Pro Pro Arg Phe Pro
50

<210> 118

<211> 57

<212> PRT

<213> Artificial

<220>

<223> Peptide

<220>

<221> MISC_FEATURE

<222> (1)..(5)

<223> Quenching domain

<220>

<221> MISC_FEATURE

<222> (6)..(18)

<223> Linker

<220>

<221> MISC_FEATURE

<222> (19)..()

<223> PR39

<400> 118

Asp Asp Asp Asp Glu Gly
1 5 10 15

Gly Glu Arg Arg Arg Pro Arg Pro Pro Tyr Leu Pro Arg Pro Arg Pro

20

10486.204-WO.ST25
25

30

Pro Pro Phe Phe Pro Pro Arg Leu Pro Pro Arg Ile Pro Pro Gly Phe
35 40 45

Pro Pro Arg Phe Pro Pro Arg Phe Pro
50 55

INTERNATIONAL SEARCH REPORT

International Application No
CT/DK2004/000605

A. CLASSIFICATION OF SUBJECT MATTER				
IPC 7	C12N5/10 A23K1/00	A23K1/17 C12N15/82		
	C07K14/47 A01K67/027	C12N15/62 C07K1/107		
C12N9/90				
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols)				
IPC 7 C07K C12N				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)				
EPO-Internal, BIOSIS, WPI Data, EMBL, Sequence Search, PAJ				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	WO 96/14413 A (AGENIX INC) 17 May 1996 (1996-05-17) cited in the application the whole document	1-13		
X	OKAMOTO MASAJI ET AL: "Enhanced expression of an antimicrobial peptide sarcotoxin IA by GUS fusion in transgenic tobacco plants" PLANT AND CELL PHYSIOLOGY, vol. 39, no. 1, January 1998 (1998-01), pages 57-63, XP000917897 ISSN: 0032-0781 cited in the application the whole document	1-13		
----- -/--				
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.				
° Special categories of cited documents : <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;"> <ul style="list-style-type: none"> *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; border: none; vertical-align: top;"> <ul style="list-style-type: none"> *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Z* document member of the same patent family </td> </tr> </table>			<ul style="list-style-type: none"> *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed 	<ul style="list-style-type: none"> *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Z* document member of the same patent family
<ul style="list-style-type: none"> *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed 	<ul style="list-style-type: none"> *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Z* document member of the same patent family 			
Date of the actual completion of the international search	Date of mailing of the international search report			
15 November 2004	23/11/2004			
Name and mailing address of the ISA	Authorized officer			
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Kools, P			

INTERNATIONAL SEARCH REPORT

International Application No

T/DK2004/000605

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WO 98/54336 A (KOREA INST SCIENCE TECHNOLOGY ;KIM SUN CHANG (KR); HONG SEUNG SUH) 3 December 1998 (1998-12-03) cited in the application the whole document</p> <p>-----</p>	14-16
Y	<p>WO 96/28559 A (UNIV BRITISH COLUMBIA) 19 September 1996 (1996-09-19) cited in the application page 6, line 26 - page 7, line 20</p> <p>-----</p>	14-16
A	<p>SHI JISHU ET AL: "Antibacterial activity of a synthetic peptide (PR-26) derived from PR-39, a proline-arginine-rich neutrophil antimicrobial peptide" ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 40, no. 1, 1996, pages 115-121, XP002276091 ISSN: 0066-4804 the whole document</p> <p>-----</p>	1-21
A	<p>MORREALE GIACOMO ET AL: "Continuous processing of fusion protein expressed as an Escherichia coli inclusion body." JOURNAL OF CHROMATOGRAPHY B, vol. 786, no. 1-2, 25 March 2003 (2003-03-25), pages 237-246, XP002276090 ISSN: 1387-2273 (ISSN print) the whole document</p> <p>-----</p>	1-21
A	<p>GACZYNSKA MARIA ET AL: "Proline- and arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity." BIOCHEMISTRY, vol. 42, no. 29, 29 July 2003 (2003-07-29), pages 8663-8670, XP002276092 ISSN: 0006-2960 (ISSN print) the whole document</p> <p>-----</p>	1-21
A	<p>SARMASIK ALIYE ET AL: "Production of transgenic medaka with increased resistance to bacterial pathogens" MARINE BIOTECHNOLOGY (NEW YORK), vol. 4, no. 3, May 2002 (2002-05), pages 310-322, XP002276093 ISSN: 1436-2228 abstract</p> <p>-----</p>	11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/DK2004/000605

Patent document cited in search report		Publication date	Patent family member(s)	Publication date			
WO 9614413	A	17-05-1996	US 5571697 A	05-11-1996			
			AU 4279896 A	31-05-1996			
			CA 2204246 A1	17-05-1996			
			CN 1171815 A	28-01-1998			
			DE 871724 T1	02-06-1999			
			EP 0871724 A1	21-10-1998			
			ES 2127164 T1	16-04-1999			
			JP 10509317 T	14-09-1998			
			WO 9614413 A1	17-05-1996			
			US 6080559 A	27-06-2000			
			US 5955316 A	21-09-1999			
			WO 9854336	A	03-12-1998	KR 263583 B1	01-08-2000
						AU 719037 B2	04-05-2000
AU 7788798 A	30-12-1998						
CA 2261569 A1	03-12-1998						
CN 1127569 B	12-11-2003						
EP 0923647 A1	23-06-1999						
JP 3362050 B2	07-01-2003						
JP 2002502246 T	22-01-2002						
WO 9854336 A1	03-12-1998						
US 6183992 B1	06-02-2001						
WO 9628559	A	19-09-1996				US 5789377 A	04-08-1998
			CA 2215362 A1	19-09-1996			
			EP 0815247 A1	07-01-1998			
			WO 9628559 A1	19-09-1996			
			JP 11503006 T	23-03-1999			
			US 5688767 A	18-11-1997			